Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Minnesota
Clinical trial register · United States · industry-sponsored

Clinical Trials in Minnesota, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9118 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 06 Oct 2026, 03:16 UTC
9118
Studies in scope
industry-sponsored, all four open statuses
4945
Recruiting now
open to new participants
2189
Lead sponsors
across recruiting studies
Top states
California 5290 Florida 4430 Illinois 2481 Georgia 2368 Arizona 2238
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca36 Novartis Pharmaceuticals23 AbbVie19 Eli Lilly and Company18 Bristol-Myers Squibb16
State
California5290 Florida4430 Illinois2481 Georgia2368 Arizona2238
All 51 states
Target enrolment
to

Trials with a site in Minnesota

924 of 9118 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
NCT07335562Systemic Sclerosis
DrugsZola-cel·Nintedanib·Tocilizumab·Fludarabine
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3
92
Arizona, Colorado, Florida, Georgia, Illinois, Massachusetts, Michigan, Minnesota
2027-02-03
Not yet open
Translational Recording and Characterization of Epilepsy Signals Using Subgaleal EEG During Standard-of-care SEEG Monitoring
NCT07821697Epilepsy (Treatment Refractory)
Adraxe Corp.
Phase EARLY_PHASE1
15
Minnesota
2026-10-15
Not yet open
Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer
NCT07578649Endometrial Neoplasms, Endometrial Cancer
DrugsPF-08634404·Keytruda·Pembrolizumab
Pfizer
Phase 3
600
Florida, Minnesota, Nevada, Ohio, Oregon, Tennessee, Texas, Virginia
2026-10-09
Not yet open
A Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia A
NCT07830732Haemophilia A
Novo Nordisk A/S
Phase 3
84
Iowa, Louisiana, Minnesota, Missouri, North Carolina, Oklahoma, Pennsylvania, Texas
2026-10-09
Not yet open
Phase 3 Trial of SRG-514 Administered Intraoperatively to Patients Undergoing Breast-Conserving Surgery
NCT07723469TNBC - Triple-Negative Breast Cancer
SURGE Therapeutics
Phase 3
400
Minnesota, New York, North Carolina
2026-10
Not yet open
Signatera Assessment in Early-Stage Endometrial Cancer
NCT07339384Endometrial Cancer
Natera, Inc.
Not applicable
1,010
Alabama, California, Florida, Illinois, Minnesota, New York, North Carolina, Ohio
2026-10
Not yet open
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
NCT07680790Non-Small Cell Lung Cancer
DrugsIza-bren·Osimertinib·Pemetrexed·Cisplatin
Bristol-Myers Squibb
Phase 3
850
California, Colorado, Florida, Hawaii, Illinois, Maryland, Minnesota, Missouri
2026-09-30
Recruiting
Phase 2/3 Efficacy and Safety of PP405 in Adult Males
NCT07819435Androgenetic Alopecia
Pelage Pharmaceuticals, Inc.
Phase 2/3
600
Arkansas, California, Florida, Georgia, Indiana, Louisiana, Minnesota, Missouri
2026-09-21
Recruiting
A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Use a Breathing Machine (PAP) (VESPER-OSA 1)
NCT07823608Apnea, Sleep Disorders, Overweight and/or Obesity
DrugBerobenatide
Pfizer
Phase 3
258
Alabama, Florida, Minnesota
2026-09-17
Recruiting
FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression
NCT07540988Interstitial Lung Diseases
DrugNerandomilast
Boehringer Ingelheim
Phase 3
466
Alabama, California, Connecticut, Florida, Indiana, Kansas, Michigan, Minnesota
2026-09-17
Recruiting
Appetite and Cognition Response to a Breakfast Cereal
NCT07782229Cognition
General Mills
Not applicable
184
Minnesota
2026-09-14
Recruiting
Transcatheter Tricuspid Valve Replacement With the Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System in Severe Tricuspid Regurgitation
NCT07321899Severe Tricuspid Regurgitation
Medtronic Cardiovascular
Not applicable
1,186
Alabama, Arizona, California, Connecticut, Georgia, Illinois, Minnesota, New York
2026-09-11
Recruiting
A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma
NCT07815665Metastatic Urothelial Carcinoma, Metastatic Urothelial Carcinoma (UC)
DrugsEnfortumab Vedotin·Pembrolizumab
Summit Therapeutics
Phase 2/3
800
Arizona, California, District of Columbia, Florida, Minnesota, Tennessee, Washington
2026-09-10
Recruiting
A Phase 1 Dose-escalation and Expansion Study of In Vivo BCMA-CAR T Cell Therapy (VV169) in Patients With Relapsed or Refractory Multiple Myeloma
NCT07802717Multiple Myeloma Refractory, Multiple Myeloma in Relapse
Vyriad, Inc.
Phase 1
40
Minnesota
2026-09-08
Not yet open
INitiation and Titration of Guideline Directed Medical TheRApy in HearT Failure Cardiogenic Shock With ImpElla 5.5 for Cardiac Recovery
NCT06965504Heart Failure, Cardiogenic Shock, Reduced Ejection Fraction Heart Failure
Abiomed Inc.
Not applicable
250
Florida, Indiana, Minnesota, Missouri, New Jersey, North Carolina, Pennsylvania, Tennessee
2026-09-01
Not yet open
Advancing Clinical Heart Failure Outcomes Leveraging Defibrillation Lead Implant System for Left Bundle Branch Area Pacing
NCT07526896Heart Failure, Systolic Bundle Branch Block, Left
Medtronic Cardiac Rhythm and Heart Failure
Not applicable
110
Minnesota
2026-09
Recruiting
A Trial to Assess the Efficacy and Safety of Engasertib in Participants With Moderate to Severe Hereditary Hemorrhagic Telangiectasia (HHT)
NCT07743671Hereditary Hemorrhagic Telangiectasia
DrugEngasertib
Vaderis Therapeutics AG
Phase 3
240
Illinois, Indiana, Minnesota, Missouri
2026-09
Recruiting
Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
NCT07691970Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus
DrugAnifrolumab
AstraZeneca
Phase 3
1,072
Arizona, California, Florida, Illinois, Michigan, Minnesota, Nebraska, New York
2026-08-31
Not yet open
An Observational Study to Learn How Mirena and Other Progestogen Treatments Are Used for Endometrial Protection in Women 40+ With a Uterus in the United States Receiving Estrogen Therapy, and Their Respective Health Outcomes
NCT07795606Estrogen Therapy
Bayer
Observational
456,000
Michigan, Minnesota
2026-08-31
Not yet open
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
NCT07735637Newly Diagnosed Multiple Myeloma (NDMM)
DrugsASCT·AZD0120·Melphalan·Lenalidomide
AstraZeneca
Phase 3
750
Florida, Georgia, Illinois, Michigan, Minnesota, Ohio, Texas, Washington
2026-08-25
Recruiting
ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa
NCT07783542Hidradenitis Suppurativa (HS)
DrugORKA-002
Oruka Therapeutics, Inc.
Phase 2
200
Alabama, California, Connecticut, Georgia, Illinois, Louisiana, Michigan, Minnesota
2026-08-21
Recruiting
Fainting Detection And Early Warning In Syncope Evaluation Study (ARISE)
NCT07502599Orthostatic Hypotension, Reflex Syncope
Boston Scientific Corporation
Observational
40
Minnesota
2026-08-06
Recruiting
A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)
NCT07421167Primary Immune Thrombocytopenia (ITP), Primary Evans Syndrome (ES)
DrugsTpo-Ra·Avatrombopag·Romiplostim·Eltrombopag
Novartis Pharmaceuticals
Phase 2
164
Arkansas, Connecticut, Florida, Illinois, Louisiana, Minnesota, Missouri, Montana
2026-08-04
Recruiting
A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants With DME - ALTO
NCT07734844Diabetic Macular Edema (DME)
DrugsTabirafusp tedromer·Eylea·Aflibercept
Kodiak Sciences Inc
Phase 3
910
California, Florida, Maryland, Minnesota, South Carolina
2026-08-03
Not yet open
A Clinical Trial To Investigate The Effect Of EA-230 On Hospital Length Of Stay In Patients With Coronary Artery Disease (CAD) Undergoing Coronary Artery Bypass Grafting (CABG) Surgery.
NCT07357675Coronary Artery Disease (CAD), Coronary Artery Bypass Graft Surgery(CABG)
EBI Anti Sepsis BV
Phase 3
300
Minnesota, Pennsylvania
2026-08-01
Recruiting
Real World Evidence of SI-BONE's iFuse TORQ TNT Advancing Treatment of Pelvic Ring Fractures
NCT07530497Fracture; Pelvic, Insufficiency Fractures, Fragility Fracture, Sacroiliac; Fusion
SI-BONE, Inc.
Observational
120
Minnesota, Pennsylvania
2026-08
Recruiting
VDyne Transcatheter Tricuspid Valve Replacement Study to Evaluate Safety and Clinical Efficacy in Patients With Symptomatic Severe Tricuspid Valve Regurgitation (TRIVITA Pivotal Trial)
NCT07516444Tricuspid Valve Regurgitation, Tricuspid Valve Disease, Cardiovascular Diseases (CVD), Heart Valve Diseases
VDyne, Inc.
Not applicable
730
Minnesota
2026-07-28
Recruiting
Evaluation of the Efficacy and Safety of Magnetic Resonance Angiography (MRA) Using Gadopiclenol Compared to Gadoterate Meglumine in the Assessment of Steno-occlusive Disease in Adult Patients With Suspected Vascular Disease
NCT07348640Steno-occlusive Disease
DrugsGadopiclenol·Gadoterate meglumine
Guerbet
Phase 3
315
California, Colorado, Illinois, Minnesota, Texas, Washington
2026-07-28
Recruiting
Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)
NCT07601425Hereditary Hemorrhagic Telangiectasia (HHT), Osler Weber Rendu Disease
DrugATV-1601
Atavistik Bio, Inc
Phase 1/2
100
Arizona, Georgia, Indiana, Massachusetts, Minnesota, Utah
2026-07-27
Recruiting
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
NCT07492680Solid Tumors
DrugsNavlimetostat·Pumitamig·Temozolomide·Cetuximab
Bristol-Myers Squibb
Phase 2
260
California, Colorado, Georgia, Maryland, Massachusetts, Michigan, Minnesota, New York
2026-07-27
Recruiting
Vorasidenib Study in Pediatric Participants With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation
NCT07286292Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation
DrugVorasidenib
Institut de Recherches Internationales Servier (I.R.I.S.)
Phase 2
10
California, Illinois, Massachusetts, Minnesota
2026-07-23
Recruiting
A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD)
NCT07366034Fibrosing Interstitial Lung Disease
DrugNerandomilast
Boehringer Ingelheim
Phase 3
35
California, Colorado, Maryland, Massachusetts, Minnesota, Ohio, Pennsylvania
2026-07-21
Recruiting
VIATORR® TIPS Study Evaluating 6-10mm Diameters (VIATIPS)
NCT07390344Ascites, Variceal Bleeding, Portal Hypertension Related to Cirrhosis
W.L.Gore & Associates
Observational
152
Georgia, Minnesota, Ohio
2026-07-20
Recruiting
Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease
NCT07549698Warm Autoimmune Hemolytic Anemia (WAIHA), ITP - Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia, Immune Thrombocytopenic Purpura
DrugZugo-cel
CRISPR Therapeutics AG
Phase 1/2
60
Minnesota, Nebraska
2026-07-17
Recruiting
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
NCT07544654Extrapulmonary Neuroendocrine Cancer (epNEC)
DrugsObrixtamig·Etoposide·Carboplatin
Boehringer Ingelheim
Phase 3
390
Arizona, California, Florida, Georgia, Illinois, Maryland, Massachusetts, Minnesota
2026-07-10
Recruiting
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
NCT07662135Type 2 Diabetes Mellitus, Type 2 Diabetes With Chronic Kidney Disease
DrugElecoglipron
AstraZeneca
Phase 3
900
Arizona, California, Florida, Illinois, Massachusetts, Michigan, Minnesota, Missouri
2026-07-06
Recruiting
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old
NCT07536269Congenital Adrenal Hyperplasia
DrugCrinecerfont
Neurocrine Switzerland GmbH
Phase 2
20
California, Colorado, Connecticut, Georgia, Illinois, Indiana, Michigan, Minnesota
2026-07-01
Recruiting
Chronic Evaluation of Novel Pacemaker System
NCT06056817Ventricular Pacing With Rate Response, Bradycardia
Calyan Technologies
Not applicable
10
Minnesota
2026-07-01
Not yet open
A Phase 1/2 Study of Safety and Tolerability of MT-125 With Chemoradiation in Patients With Newly Diagnosed MGMT Methylated Glioblastoma
NCT07604285Glioblastoma
DrugMT-125
Myosin Therapeutics Inc.
Phase 1/2
36
Arizona, Florida, Minnesota
2026-07
Recruiting
EXACT Study: A Blinded Study in Patients With Alport Syndrome to Evaluate Exaluren Efficacy and Safety
NCT07523581Alport Syndrome, X-Linked, Alport Syndrome, Autosomal Recessive
Eloxx Pharmaceuticals, Inc.
Phase 2
24
California, Colorado, Minnesota, New Jersey, Pennsylvania, Texas
2026-06-30
Recruiting
A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
NCT07673887Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsASP2138·Folinic acid·Adrucil·Capecitabine
Astellas Pharma Global Development, Inc.
Phase 3
570
Minnesota
2026-06-30
Not yet open
AUR103 Calcium in Advanced Neuroendocrine Tumours (BHARAT-3 Study)
NCT07640737Neuroendocrine (NE) Tumors, Advanced NET of GI Origin
Aurigene Discovery Technologies Limited
Phase 2
30
Arizona, California, Florida, Minnesota, Pennsylvania
2026-06-30
Recruiting
To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment
NCT07684820Chronic Obstructive Pulmonary Disease (COPD)
Expedition Therapeutics, Inc
Phase 2
600
Arizona, California, Colorado, Florida, Georgia, Indiana, Kansas, Minnesota
2026-06-30
Recruiting
A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)
NCT07614984Lipoprotein(a)
DrugsHRS-5346·Enlicitide
Merck Sharp & Dohme LLC
Phase 2
750
Alabama, California, Connecticut, Florida, Maryland, Michigan, Minnesota, Montana
2026-06-30
Recruiting
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis
NCT07224672Amyloidosis
DrugsBelantamab mafodotin·Bortezomib·Dexamethasone·Cyclophosphamide
GlaxoSmithKline
Phase 2
60
Minnesota
2026-06-24
Recruiting
KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)
NCT07406633GIST - Gastrointestinal Stromal Tumor, GIST, GIST Metastatic Cancer, Gastro Intestinal Stromal Tumour
DrugsKQB198·Imatinib
Kumquat Biosciences Inc.
Phase 2
46
California, Florida, Illinois, Iowa, Massachusetts, Michigan, Minnesota, New York
2026-06-23
Recruiting
Study of the Shockwave Medical SkyRunner Carotid Intravascular Lithotripsy (IVL) System for the Treatment of Calcified Carotid Arteries Prior to Trans-Carotid Stenting (SKYWARD Trans-Carotid IDE [Investigational Device Exemption] Study)
NCT07062471Carotid Artery Calcification, Carotid Artery Diseases
Shockwave Medical, Inc.
Not applicable
185
Arkansas, California, District of Columbia, Florida, Illinois, Massachusetts, Michigan, Minnesota
2026-06-22
Recruiting
Establishing the Preliminary Utility of a Novel Pediatric Manual Mobile Standing Wheelchair
NCT07290556Spina Bifida
Optimal Mobility, Inc
Not applicable
30
Minnesota
2026-06-18
Recruiting
A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity
NCT07728383Obesity & Overweight
Gila Therapeutics, Inc.
Phase 4
40
Minnesota
2026-06-17
Recruiting
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
NCT07644559Pancreatic Ductal Adenocarcinoma (PDAC), G12D Mutated KRAS
DrugsVS-7375·Cetuximab
Verastem, Inc.
Phase 2
180
California, Florida, Maryland, Massachusetts, Michigan, Minnesota, Missouri, New Jersey
2026-06-16
Recruiting
xDot Access Management System Early Feasibility Study
NCT07464353Vascular Closure Devices
xDot Medical, Inc
Not applicable
30
Illinois, Minnesota, Oklahoma, South Dakota, Wisconsin
2026-06-16
Recruiting
A Study With NVC-001 in Patients With LMNA-related Dilated Cardiomyopathy (SUNBEAM-LMNA)
NCT07606274LMNA-Related Dilated Cardiomyopathy
Nuevocor Pte. Ltd.
Phase 1/2
21
Alabama, California, Massachusetts, Michigan, Minnesota, Ohio, Texas
2026-06-16
Recruiting
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)
NCT07637734Common Warts, Common Warts (Verruca Vulgaris), Human Papilloma Virus (HPV), Warts
Verrica Pharmaceuticals Inc.
Phase 3
300
California, Florida, Illinois, Kansas, Louisiana, Massachusetts, Minnesota, Nebraska
2026-06-15
Recruiting
IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)
NCT07104032Relapsed/Refractory Primary Central Nervous System Lymphoma
DrugsTirabrutinib·Temozolomide·Rituximab
Ono Pharmaceutical Co., Ltd.
Phase 3
132
Arizona, California, Connecticut, District of Columbia, Florida, Maryland, Massachusetts, Minnesota
2026-06-12
Active, closed
Open-Label Extension Study of BBP-418 (Ribitol) for LGMD2I/R9
NCT07678775Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)
DrugRibitol
ML Bio Solutions, Inc.
Phase 3
107
Arkansas, California, Colorado, Florida, Iowa, Kansas, Maryland, Minnesota
2026-06-05
Recruiting
Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
NCT07539090Healthy Participants
DrugVimseltinib
Deciphera Pharmaceuticals, LLC
Phase 1
24
Minnesota
2026-06-05
Recruiting
A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events
NCT07448038Atherosclerosis
Genentech, Inc.
Phase 2
162
California, Connecticut, Florida, Indiana, Michigan, Minnesota, Missouri, Nebraska
2026-06-05
Recruiting
Water Vapor Ablation for Prostate Cancer: Long-Term Registry
NCT07455058Prostate Cancer
Francis Medical Inc.
Observational
2,500
Louisiana, Minnesota, Texas, Virginia
2026-06-05
Recruiting
A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement
NCT07359820FGFR2 Gene Fusion/Rearrangement, Other Solid Tumors, Adult
Elevar Therapeutics
Phase 2
30
Arizona, Florida, Illinois, Massachusetts, Minnesota, New York, Texas
2026-06-04
Recruiting
A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy
NCT07498426Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
Novartis Pharmaceuticals
Phase 3
300
Arizona, California, Colorado, Florida, Minnesota
2026-06-03
Recruiting
Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer
NCT07590934Metastatic Prostate Cancer
DrugsAZD2287·FPI-2265·Palacaparib·Docetaxel
AstraZeneca
Phase 1/2
152
California, Florida, Louisiana, Minnesota, Nebraska, New York, Oregon, Texas
2026-06-03
Recruiting
Proof of Concept Study of Vaginal AZU-101 in Vulvovaginal Atrophy in Postmenopausal Women
NCT06197568Vulvo Vaginal Atrophy (VVA)
Azure Biotech Inc.
Phase 2
90
Minnesota
2026-06-01
Not yet open
Evaluation of the Efficacy, Safety, and Tolerability of LevoCept
NCT04457076Contraception, Women at Risk for Pregnancy
Sebela Women's Health Inc.
Phase 3
1,525
California, Colorado, Georgia, Hawaii, Indiana, Minnesota, Missouri, Nevada
2026-06-01
Recruiting
A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia
NCT06712654Hyperphosphatemia, Chronic Kidney Disease Requiring Chronic Dialysis, End Stage Renal Disease on Dialysis
R1 Therapeutics
Phase 2
168
Alabama, California, Colorado, Connecticut, Florida, Georgia, Michigan, Minnesota
2026-06-01
Not yet open
Simultaneous Measurement of EpicArdial and Microvascular ResisTance Via Angiographic FLOW Study
NCT07676097Non-obstructive Coronary Disease, Acute or Chronic Coronary Artery Disease
AngioInsight
Observational
620
California, District of Columbia, Minnesota, New Jersey, New York, Ohio, Tennessee
2026-06
Recruiting
Immune Modulation During Palynziq® Treatment in Adults (IMPALA)
NCT07477691Phenylketonuria
DrugsPegvaliase·Methotrexate
BioMarin Pharmaceutical
Phase 4
12
California, Colorado, Florida, Illinois, Indiana, Minnesota, New York, Oregon
2026-05-29
Recruiting
A Phase 1 Study of the Safety and Tolerability of CTX-10726
NCT07419841Gastroesophageal Cancer (GC), Hepatocellular Carcinoma (HCC), Endometrial Cancer, Renal Cell Carcinoma (RCC)
Compass Therapeutics
Phase 1
70
Arizona, Florida, Minnesota, Nebraska, New York, Pennsylvania, South Carolina, Tennessee
2026-05-28
Recruiting
A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine
NCT07609914Acute Treatment of Migraine
DrugRimegepant
Pfizer
Phase 4
400
California, Florida, Indiana, Massachusetts, Michigan, Minnesota, Mississippi, Nevada
2026-05-28
Recruiting
Multi-Center, Prospective, Non-Interventional Study in Subjects With Limbal Stem Cell Deficiency
NCT07636590Limbal Stem Cell Deficiency
Claris Biotherapeutics, Inc.
Observational
500
Indiana, Kansas, Kentucky, Minnesota, Oregon, Tennessee, Texas
2026-05-22
Recruiting
ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome
NCT07531745Dravet Syndrome
Ionis Pharmaceuticals, Inc.
Phase 1/2
32
Michigan, Minnesota, North Carolina, Tennessee, Washington
2026-05-21
Recruiting
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
NCT07393282High Risk Smoldering Multiple Myeloma (HR-SMM)
DrugsLinvoseltamab·Darzalex·Daratumumab
Regeneron Pharmaceuticals
Phase 3
270
Arizona, Georgia, Massachusetts, Michigan, Minnesota, New York, Ohio
2026-05-21
Recruiting
A Study of JNJ-1761981 in Participants With Solid Tumors
NCT07525141Neoplasms
DrugCetrelimab
Johnson & Johnson Enterprise Innovation Inc.
Phase 1
66
Florida, Minnesota, New York, Texas
2026-05-18
Recruiting
A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants
NCT07588139Healthy Participants
DrugsPovorcitinib·Ruxolitinib
Incyte Corporation
Phase 1
24
Minnesota
2026-05-18
Recruiting
An Exploratory Efficacy and Safety Study of DFL24498 Topical Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye Disease
NCT07503886Dry Eye Disease (DED)
DrugDFL24498
Dompé Farmaceutici S.p.A
Phase 2
417
Arizona, California, Florida, Georgia, Indiana, Minnesota, Missouri, North Carolina
2026-05-12
Recruiting
A Study of TAK-505 in Adults With Solid Tumors
NCT07436728Malignant Solid Tumors
Takeda
Phase 1/2
151
California, Florida, Minnesota, New York, Ohio, Tennessee, Texas, Virginia
2026-05-11
Recruiting
A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
NCT07265674Advanced Biliary Tract Cancer, Biliary Tract Cancer (BTC)
J-Pharma Co., Ltd.
Phase 3
480
California, Florida, Illinois, Kentucky, Louisiana, Michigan, Minnesota, Nevada
2026-05-11
Recruiting
Pivotal Study of the SUpira System in Patients Undergoing High-Risk Percutaneous COronaRy InTervention (HRPCI)
NCT07296744Coronary Artery Disease, High Risk Percutaneous Coronary Intervention, Interventional Cardiology, Mechanical Circulatory Support
Supira Medical
Not applicable
358
California, Georgia, Illinois, Michigan, Minnesota, Missouri, New Jersey, New York
2026-05-11
Recruiting
A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism
NCT07081997Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
Ascendis Pharma Bone Diseases A/S
Phase 3
36
Colorado, Illinois, Minnesota, Nevada, New York, North Carolina, Texas, Washington
2026-05-07
Recruiting
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
NCT07415031Solid Tumors
DrugsAdagrasib·Fluorouracil·Leucovorin·Cetuximab
Mirati Therapeutics Inc.
Phase 2
170
Arizona, California, Delaware, Florida, Kansas, Massachusetts, Minnesota, Nebraska
2026-05-06
Recruiting
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)
NCT07545759Irritable Bowel Syndrome, Diarrhea
DrugBrenipatide
Eli Lilly and Company
Phase 2
531
Arizona, California, Florida, Illinois, Indiana, Kentucky, Michigan, Minnesota
2026-05-06
Recruiting
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
NCT07549412Metastatic Colorectal Cancer
DrugsTrifluridine/Tipiracil·Bevacizumab
EMD Serono Research & Development Institute, Inc.
Phase 3
1,020
Colorado, Florida, Illinois, Michigan, Minnesota, Missouri, New York, Tennessee
2026-05-06
Recruiting
A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)
NCT07555483Alpha 1 Antitrypsin Deficiency
Grifols Therapeutics LLC
Phase 3
40
Alabama, Arizona, California, Florida, Minnesota, Ohio, South Carolina, Texas
2026-05-05
Recruiting
MyokinE100 System: Closed Loop Electrical Muscle Stimulation to Mitigate ICU Acquired Weakness in Medical ICU Patients
NCT07362862Sepsis, Critical Illness, ICU-acquired Muscle Weakness, ICU-acquired Weakness
Health Discovery Labs
Not applicable
50
Minnesota, Texas
2026-05-05
Recruiting
A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants With Lichen Sclerosus
NCT07335588Lichen Sclerosus
DrugDelgocitinib
LEO Pharma
Phase 3
652
Alabama, Arizona, California, District of Columbia, Florida, Minnesota, New York, Ohio
2026-05-01
Recruiting
Evaluation of Liver Stiffness Performance, by FibroScan®, to Detect Elevated Central Venous Pressure (CVP)
NCT07222813Heart Failure, Heart Failure - NYHA II - IV
Echosens
Not applicable
149
California, Minnesota, South Carolina, Texas
2026-04-23
Recruiting
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
NCT07271667Chronic Lymphocytic Leukemia, B-cell Malignancies
DrugsEmavusertib·Zanubrutinib
Curis, Inc.
Phase 2
108
Florida, Minnesota, New Jersey, Ohio, Pennsylvania, Texas
2026-04-23
Recruiting
A Study of TSRA-196 in Adults With PiZZ Alpha-1 Antitrypsin Deficiency (AATD)
NCT07227207Alpha-1 Antitrypsin Deficiency (AATD)
Tessera Therapeutics, Inc.
Phase 1/2
72
Florida, Massachusetts, Minnesota, South Carolina, Washington
2026-04-21
Recruiting
Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
NCT07531095Small Cell Lung Cancer
DrugsZL-1310·Tarlatamab·Durvalumab
Amgen
Phase 1
160
Arizona, Florida, Illinois, Minnesota, New York, Tennessee, Virginia
2026-04-21
Recruiting
The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study
NCT06796504Relapsing Remitting Multiple Sclerosis
SetPoint Medical Corporation
Not applicable
60
California, Georgia, Maryland, Minnesota, Texas, Washington, West Virginia, Wisconsin
2026-04-17
Recruiting
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
NCT07226843Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma
DrugRituximab
Eli Lilly and Company
Phase 1
460
Arizona, California, Colorado, Florida, Georgia, Massachusetts, Minnesota, New York
2026-04-17
Recruiting
A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in Subjects With BAG3 Dilated Cardiomyopathy
NCT07137338Dilated Cardiomyopathy (DCM)
Rocket Pharmaceuticals Inc.
Phase 1
8
California, Minnesota, South Carolina
2026-04-17
By invitation
A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) or Microvascular Inflammation (MVI) (TRANSCEND/TRANSPIRE LTE)
NCT07444489Antibody-mediated Rejection, Microvascular Inflammation
DrugFelzartamab
Biogen
Phase 3
201
California, Minnesota, Missouri, Nebraska, New Jersey, Ohio, Pennsylvania, Virginia
2026-04-16
Recruiting
EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
NCT07287670Diffuse Cutaneous Systemic Sclerosis
Mediar Therapeutics
Phase 2
85
Arizona, California, Colorado, Florida, Kansas, Maryland, Massachusetts, Minnesota
2026-04-16
Recruiting
A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis Pigmentosa
NCT06891885Retinitis Pigmentosa
Sumitomo Pharma America, Inc.
Phase 1/2
12
Massachusetts, Minnesota
2026-04-16
Recruiting
Randomized Study on Transoral Outlet Reduction and Lifestyle Changes for Weight Regain After Gastric Bypass
NCT07015424Weight Regain, Weight Loss
Boston Scientific Corporation
Not applicable
108
California, Florida, Illinois, Maryland, Minnesota, New York, Texas, West Virginia
2026-04-14
Recruiting
AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
NCT07533175Diabetes Mellitus, Overweight, Obesity
DrugNNC0487-0111
Novo Nordisk A/S
Phase 3
630
Alabama, California, Florida, Minnesota, New York, South Carolina, Tennessee, Texas
2026-04-13
Recruiting
Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)
NCT07297979Ewing Sarcoma
DrugXaluritamig
Amgen
Phase 1
50
California, Maryland, Massachusetts, Minnesota, New York, Pennsylvania, Texas
2026-04-08
Recruiting
A Gaucher Disease Gene Therapy Trial With FLT201
NCT07223944Gaucher Disease Type 1
Spur Therapeutics
Phase 3
45
California, Colorado, Georgia, Iowa, Minnesota, New Jersey, New York, North Carolina
2026-04-07
Recruiting
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
NCT07405801Breast Cancer
DrugsInavolisib·Ribociclib·Fulvestrant
Hoffmann-La Roche
Phase 2
80
California, Florida, Minnesota, South Dakota, Wisconsin
2026-04-07
Active, closed
A Pivotal Study to Evaluate the Clinical Benefit, Performance and Safety of a Totally Implantable Cochlear Implant (TICI) System in Adults
NCT07287124Hearing Loss, Bilateral Sensorineural
Cochlear
Not applicable
56
Colorado, Florida, Iowa, Michigan, Minnesota, Missouri, New York, Ohio
2026-04-03
Recruiting
A Phase 2/3 Study on the Efficacy and Safety of Mangaciclanol for Contrast-Enhanced MRI of CNS or Body in Adult Patients
NCT07472491Known or Highly Suspected Central Nervous System (CNS) Lesion, Known or Highly Suspected Body (Excluding CNS) Lesion
DrugGadobutrol
GE Healthcare
Phase 2/3
640
Minnesota, Texas
2026-04-01
Recruiting
A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients
NCT07185880Glioblastoma (GBM)
DrugMT-125
Myosin Therapeutics Inc.
Phase 1/2
36
Arizona, Florida, Minnesota
2026-04-01
By invitation
A Study of Outcomes Following Bio-Reinforced Canaloplasty in Eyes With Open-Angle Glaucoma
NCT07520175Open-Angle Glaucoma
Iantrek, Inc.
Observational
300
California, Minnesota, Oregon, Pennsylvania, Texas
2026-04-01
Recruiting
Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung
NCT07499674Lung Cancer, Lung Metastases
Vergent Bioscience, Inc.
Phase 3
132
California, Colorado, Florida, Michigan, Minnesota, Pennsylvania, Texas
2026-03-31
Recruiting
A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma Patients
NCT07549321High-Risk Neuroblastoma
DrugsTemozolomide·Irinotecan
Renaissance Pharma Ltd.
Phase 2/3
144
Colorado, Minnesota, New York, North Carolina, Pennsylvania
2026-03-30
Recruiting
A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)
NCT07199465Cytomegalovirus Prophylaxis
DrugLetermovir
Merck Sharp & Dohme LLC
Phase 1
40
Alabama, California, Colorado, Florida, Georgia, Illinois, Michigan, Minnesota
2026-03-30
Recruiting
Acute Pulmonary Embolism Treatment With the AlphaVac Multipurpose Mechanical Aspiration System and the AlphaReturn Blood Management System: Evaluation of Safety and Effectiveness
NCT07280247Pulmonary Embolism Acute
Angiodynamics, Inc.
Not applicable
39
Minnesota, New York, Ohio, Texas
2026-03-30
By invitation
A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal Melanoma
NCT07338968Choroidal Melanoma, Indeterminate Lesions
Aura Biosciences
Observational
100
California, Michigan, Minnesota, Oklahoma, South Carolina, Tennessee, Texas, Utah
2026-03-27
Recruiting
A Study to Assess the Effects of Zigakibart on IgA Nephropathy.
NCT07146906Immunoglobulin A Nephropathy (IgAN)
DrugZigakibart
Novartis Pharmaceuticals
Phase 2
32
Colorado, Georgia, Iowa, Minnesota
2026-03-26
Recruiting
Transition to KPL-387 Monotherapy Dosing & Administration Study
NCT07288216Recurrent Pericarditis, Heart Diseases, Pericarditis
DrugKPL-387
Kiniksa Pharmaceuticals International, plc
Phase 2
120
Arizona, California, Florida, Illinois, Maryland, Massachusetts, Minnesota, Missouri
2026-03-25
Recruiting
A Long-Term Observational Study of Patients With Fucosidosis
NCT07615400Fucosidosis
JCR Pharmaceuticals Co., Ltd.
Observational
57
California, Minnesota
2026-03-25
Recruiting
A Study of Mirikizumab Solution (LY3074828) in Healthy Participants
NCT07446101Healthy
DrugMirikizumab
Eli Lilly and Company
Phase 1
450
Florida, Minnesota, Texas, Wisconsin
2026-03-24
Recruiting
Continuous Dual Aspiration Technique With Zoom System for Stroke
NCT07491952Ischemic Stroke, Acute Stroke
Imperative Care, Inc.
Observational
750
Alabama, California, Florida, Georgia, Louisiana, Maryland, Minnesota, New York
2026-03-24
Active, closed
MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial
NCT07505303Adult Obesity, Weight Management
DrugsECC4703·Semaglutide
Eccogene
Phase 2
151
Alabama, California, Florida, Georgia, Minnesota, Nebraska, North Carolina, Ohio
2026-03-23
Recruiting
A Study of JPH034 in Healthy Adult Participants
NCT07534657Health Adult Subjects
J-Pharma Co., Ltd.
Phase 1
40
Minnesota
2026-03-22
Recruiting
BIOTRONIK Investigation of the LivIQ Leadless Pacemaker System
NCT07118358Leadless Pacemaker, Bradycardia, AV Block, Cardiac Rhythm Disorder
Biotronik, Inc.
Not applicable
325
California, Colorado, Florida, Kentucky, Michigan, Minnesota, Missouri, New York
2026-03-16
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
NCT07221149Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
DrugsPumitamig·Folfox·Nivolumab
Bristol-Myers Squibb
Phase 2/3
690
Arizona, California, Florida, Georgia, Illinois, Iowa, Minnesota, Missouri
2026-03-13
By invitation
Long-Term Open-Label Extension Study of Oral Levosimendan
NCT07436689Pulmonary Hypertension Associated With HFpEF
DrugTNX-103
Tenax Therapeutics, Inc.
Phase 3
800
Illinois, Massachusetts, Minnesota, Missouri, Nebraska, North Carolina, South Carolina, Wisconsin
2026-03-13
Active, closed
A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick Exposure
NCT07562087Lyme Disease
Tarsus Pharmaceuticals, Inc.
Phase 2
722
Maryland, Massachusetts, Minnesota, New Jersey, New York, Pennsylvania, Rhode Island
2026-03-09
Recruiting
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07491445Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
DrugsCetuximab·Nab-paclitaxel·Gemcitabine
Revolution Medicines, Inc.
Phase 3
900
Arizona, California, Florida, Maryland, Massachusetts, Michigan, Minnesota, Nevada
2026-03-09
Recruiting
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT07218341Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic
DrugsIdelalisib·Pirtobrutinib
Eli Lilly and Company
Phase 4
150
Alabama, Arizona, Florida, Minnesota, New York, Ohio, Texas
2026-03-09
Recruiting
Evaluation of the Efficacy and Safety of THRV-1268 in Participants With Long QT Syndrome Type 2 (LQTS2) and Type 3 (LQTS3)
NCT07277582Long QT Syndrome (LQTS) 2
Thryv Therapeutics, Inc.
Phase 2/3
84
Arizona, California, Illinois, Massachusetts, Michigan, Minnesota, New York, North Carolina
2026-03-07
Recruiting
A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
NCT07450859Pancreatic Ductal Adenocarcinoma (PDAC)
DrugNuzefatide pevedotin
BicycleTx Limited
Phase 2
39
Arizona, Florida, Minnesota, Missouri, New York, Pennsylvania
2026-03-05
Recruiting
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
NCT07277413NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma, Adenocarcinoma of Esophagus
DrugIDE397
IDEAYA Biosciences
Phase 1
260
Arizona, California, District of Columbia, Florida, Illinois, Minnesota, Nebraska, New Jersey
2026-03-04
Recruiting
Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
NCT07477639Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS), Multiple Sclerosis, Multiple Sclerosis (MS) Primary Progressive
DrugBendamustine
Tr1X, Inc.
Phase 1/2
39
California, Kansas, Minnesota, Missouri, New York, North Carolina, Ohio, Washington
2026-03-01
Recruiting
C. Difficile Toxin Levels in Stool From Healthy Individuals Following Standard of Care Antibiotic Treatment for CDI.
NCT07250724Clostridioides Difficile Infection Recurrence
Bactolife A/S
Observational
60
Georgia, Michigan, Minnesota, Wisconsin
2026-03-01
Recruiting
Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
NCT07379827Schizophrenia
DrugKarXT
Bristol-Myers Squibb
Observational
1,500
Arkansas, California, Florida, Georgia, Illinois, Michigan, Minnesota, Nebraska
2026-02-26
Recruiting
A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
NCT07148089Catecholaminergic Polymorphic Ventricular Tachycardia
Solid Biosciences Inc.
Phase 1
18
Massachusetts, Minnesota, Ohio, Pennsylvania
2026-02-23
Recruiting
A Multicenter, Randomized, Vehicle-Controlled, Double-Masked to Open-Label Study to Evaluate the Safety and Efficacy of Lacripep in Subjects With Neurotrophic Keratitis
NCT07568730Neurotrophic Keratitis
TearSolutions, Inc.
Phase 2
54
Florida, Indiana, Massachusetts, Minnesota, Missouri, New York
2026-02-19
Recruiting
A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH)
NCT07491458MASH - Metabolic Dysfunction-Associated Steatohepatitis
DrugHU6
Rivus Pharmaceuticals, Inc.
Phase 2
180
Arizona, Arkansas, California, Florida, Illinois, Louisiana, Michigan, Minnesota
2026-02-13
Recruiting
A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis
NCT07201922Familial Pulmonary Fibrosis, Interstitial Lung Abnormalities, Interstitial Lung Diseases
DrugNerandomilast
Boehringer Ingelheim
Phase 3
80
California, Colorado, Florida, Kansas, Massachusetts, Michigan, Minnesota, New York
2026-02-10
Recruiting
Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants Undergoing Open Abdominal Ventral Hernia Repair
NCT07226791Ventral Hernia
DrugAGN-151607-DP
AbbVie
Phase 2
200
California, Florida, Illinois, Kansas, Minnesota, North Carolina, Ohio, Pennsylvania
2026-02-04
Recruiting
TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
NCT07223203Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy, hATTR-PN
DrugsNucresiran·Vutrisiran
Alnylam Pharmaceuticals
Phase 3
125
Colorado, Illinois, Maryland, Massachusetts, Minnesota, New York, North Carolina, Tennessee
2026-02-03
Active, closed
Evaluate RLS-1496 Topical Cream for Actinic Keratosis
NCT07340697Actinic Keratosis (AK)
Rubedo Life Sciences, Inc.
Phase 1/2
24
Arkansas, Minnesota, Nebraska, Texas
2026-02-03
Recruiting
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
NCT07397338Advanced Solid Tumors, Metastatic Solid Tumors, Non-small Cell Lung Cancer (NSCLC), NSCLC
DrugsElironrasib·Zoldonrasib·Ivonescimab·Cetuximab
Revolution Medicines, Inc.
Phase 1/2
370
California, Connecticut, Minnesota, Tennessee, Texas, Virginia
2026-01-30
Recruiting
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function
NCT07315360Renal Impairment, Healthy
DrugPF-07328948
Pfizer
Phase 1
28
California, Florida, Minnesota
2026-01-28
Recruiting
Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma
NCT07225621Glioblastoma, GBM
Alpheus Medical, Inc.
Phase 2
103
Massachusetts, Minnesota, New York, Ohio, Pennsylvania
2026-01-28
Recruiting
Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07259317Adenocarcinoma, Carcinoma, Pancreatic Ductal
DrugsRelacorilant·Nab-paclitaxel·Gemcitabine
Corcept Therapeutics
Phase 2
80
Arizona, California, Florida, Georgia, Indiana, Kansas, Michigan, Minnesota
2026-01-27
Recruiting
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
NCT07287917Melanoma (Skin Cancer), HER2-low Hormone Receptor Positive Breast Cancer
DrugsDifluoromethylornithine·DFMO·Capivasertib·Fulvestrant
Aminex Therapeutics, Inc.
Phase 1/2
92
Arizona, California, Colorado, Kansas, Michigan, Minnesota, New York, Ohio
2026-01-26
Recruiting
Neoadjuvant Darovasertib in Primary Uveal Melanoma
NCT07015190Uveal Melanoma
DrugDarovasertib
IDEAYA Biosciences
Phase 3
520
Arizona, California, Colorado, Florida, Maryland, Massachusetts, Michigan, Minnesota
2026-01-25
Recruiting
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
NCT07277231Chronic Lymphocytic Leukemia
DrugsSonrotoclax·Venclyxto·Acalabrutinib·Venclexta
BeOne Medicines
Phase 3
500
California, Colorado, Florida, Illinois, Louisiana, Massachusetts, Minnesota, Nebraska
2026-01-22
Recruiting
Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis
NCT07332091Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis
CSL Behring
Phase 2
84
Arizona, California, Florida, Indiana, Louisiana, Maryland, Michigan, Minnesota
2026-01-22
Recruiting
A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)
NCT07159841Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
DrugAtumelnant
Crinetics Pharmaceuticals Inc.
Phase 2/3
153
California, Illinois, Massachusetts, Michigan, Minnesota, New Jersey, New York, Pennsylvania
2026-01-22
Not yet open
Clinical Accuracy Validation of the Moni-Patch Temperature Monitoring Patch System
NCT07397078Body Temperature, Febrile
Murata Vios, Inc.
Not applicable
105
Minnesota
2026-01-21
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
NCT07216703Cervical Cancer
DrugsMvasi·Sacituzumab tirumotecan·Paraplatin·Avastin
Merck Sharp & Dohme LLC
Phase 3
1,023
Alabama, California, Florida, Georgia, Louisiana, Maryland, Minnesota, Nevada
2026-01-19
By invitation
Examining the Impact of a Digital Health Program and TENS Device for Patients With Chronic Low Back Pain
NCT07011537Back Pain Lower Back Chronic, Chronic Pain, Musculoskeletal Pain
Hinge Health, Inc
Not applicable
196
Minnesota
2026-01-16
Active, closed
Horizon 360 Protocol for the Treatment of Paroxysmal Atrial Fibrillation With the Sphere-360™ Catheter and Affera™ Mapping and Ablation System (Horizon 360)
NCT07308847Paroxysmal AF
Medtronic Cardiac Ablation Solutions
Not applicable
300
Arkansas, California, Florida, Georgia, Illinois, Kansas, Massachusetts, Minnesota
2026-01-15
Recruiting
A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
NCT07226427Platinum-resistant Ovarian Cancer
Stemline Therapeutics, Inc.
Phase 1
100
Arkansas, Connecticut, Florida, Massachusetts, Michigan, Minnesota, Virginia
2026-01-10
Active, closed
AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)
NCT07285694Metastatic Castration Resistant Prostate Cancer (mCRPC)
Arsenal Biosciences, Inc.
Phase 1/2
190
California, Colorado, Iowa, Kansas, Minnesota, New York, Washington
2026-01-09
Recruiting
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
NCT07227454Depressive Disorder, Major
DrugsEsketamine·Midazolam
Janssen Research & Development, LLC
Phase 3
258
Alabama, District of Columbia, Georgia, Illinois, Maryland, Massachusetts, Minnesota, Ohio
2026-01-08
Recruiting
A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants
NCT06904261Fabry Disease
DrugMigalastat HCl
Amicus Therapeutics
Phase 3
8
Georgia, Minnesota, North Carolina, Ohio, Pennsylvania, Virginia
2026-01-08
Recruiting
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
NCT07095452Multiple Myeloma
DrugsEtentamig·Daratumumab·Lenalidomide·Dexamethasone
AbbVie
Phase 2/3
680
Arizona, California, Colorado, Georgia, Indiana, Minnesota, New York, North Carolina
2026-01-08
Recruiting
Safety, Tolerability, and Pharmacokinetics of ASCT-83 in Healthy Adults
NCT07363395Neuropathic Pain
Alcamena Stem Cell Therapeutics
Phase 1
72
Minnesota
2026-01-06
Recruiting
A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation
NCT07219043Microvascular Inflammation
DrugFelzartamab
Biogen
Phase 2
81
California, Colorado, Kansas, Michigan, Minnesota, Missouri, Nebraska, New Jersey
2026-01-05
Recruiting
Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma
NCT07282587Advanced Pheochromocytoma and Paraganglioma, PCPG
DrugONC206
Jazz Pharmaceuticals
Phase 2
90
California, Colorado, Michigan, Minnesota, Missouri, New York, Pennsylvania, Utah
2026-01-02
Recruiting
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous SCC for Immunocompromised Patients
NCT06615635Squamous Cell Carcinoma, Alpha Radiation, Immunocompromised, Carcinoma, Squamous
Alpha Tau Medical LTD.
Not applicable
28
Arizona, Florida, Georgia, Minnesota, New York
2026-01-01
Recruiting
Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia
NCT07033598Leukemia, Myelomonocytic, Chronic
DrugsPacritinib·Hydroxyurea
Theradex
Phase 2
66
Florida, Georgia, Minnesota, Texas
2026-01-01
Recruiting
Post-Market Study of the Signia Circular Stapler With Tri-Staple Technology in Left-sided Colon, Sigmoid, and Rectal Resections
NCT07351071Colorectal Anastomosis, Left-sided Colon Resection, Anastomotic Leak, Anastomotic Complication
Medtronic - MITG
Not applicable
137
Connecticut, Florida, Georgia, Massachusetts, Minnesota, North Carolina, Ohio, Pennsylvania
2025-12-30
Recruiting
Renal Pelvic Denervation Pilot Trial
NCT07005050Uncontrolled Hypertension
Verve Medical, Inc
Not applicable
60
Alabama, Arizona, Minnesota, Nevada
2025-12-30
Recruiting
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
NCT07361562Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer, ERBB2 Gene Amplification, HER2 Overexpression
Cogent Biosciences, Inc.
Phase 1
100
Arizona, Connecticut, Florida, Illinois, Louisiana, Michigan, Minnesota, Missouri
2025-12-30
Recruiting
Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH
NCT07335601MASH - Metabolic Dysfunction-Associated Steatohepatitis
DrugResmetirom
Madrigal Pharmaceuticals, Inc.
Phase 2
120
California, Colorado, District of Columbia, Illinois, Minnesota, Nebraska, New York, Tennessee
2025-12-29
Recruiting
First-in-human Study of the Safety, Tolerability, Pharmacokinetics, and Food Effect of ACCG-2671
NCT07815678Obesity
Aconcagua Bio, Inc. a wholly owned subsidiary of Structure Therapeutics
Phase 1/2
164
California, Georgia, Minnesota, Missouri, Texas
2025-12-29
Recruiting
Diagnosing Epilepsy To EffeCT Change Long-Term Follow-Up
NCT07110454Epilepsy, Epilepsy (Treatment Refractory)
Epiminder America, Inc.
Observational
210
Alabama, Arizona, California, Connecticut, Florida, Indiana, Massachusetts, Minnesota
2025-12-23
Recruiting
Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis
NCT06975787Lupus Nephritis (LN)
DrugsVonsetamig·Odronextamab
Regeneron Pharmaceuticals
Phase 1
90
California, Minnesota, Texas
2025-12-22
Recruiting
NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease
NCT07305818Graves Disease
Merida Biosciences
Phase 1
100
California, Florida, Massachusetts, Minnesota, North Carolina, Ohio, Pennsylvania, Texas
2025-12-19
Recruiting
The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia.
NCT07224464Metastatic Solid Tumors, Stage 4 Cancer
New Phase Ltd.
Not applicable
12
Minnesota
2025-12-16
Recruiting
The Effect of Cosmetic Formulations on the Appearance of Grey Hair.
NCT07280676Hair Graying
Unilever R&D
Not applicable
380
Minnesota
2025-12-15
Recruiting
A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures
NCT07219407Focal Epilepsy, Epilepsy, Refractory Focal Epilepsy, Seizure
DrugRAP-219
Rapport Therapeutics Inc.
Phase 2
30
Idaho, Minnesota, New York, Ohio, Pennsylvania, Tennessee, Texas
2025-12-15
Recruiting
A Long-term Follow-up Study in Patients Who Received BEAM-101
NCT07373639Hemoglobinopathy, Sickle Cell Disease
Beam Therapeutics Inc.
Observational
50
Alabama, Arizona, Florida, Georgia, Massachusetts, Michigan, Minnesota, Missouri
2025-12-15
Recruiting
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
NCT06947928Advanced Or Metastatic Merkel Cell Carcinoma
DrugsIFx-Hu2.0·Keytruda·Pembrolizumab
TuHURA Biosciences, Inc.
Phase 2/3
118
California, Colorado, Florida, Massachusetts, Minnesota, New Jersey, North Carolina, Pennsylvania
2025-12-11
Active, closed
Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome
NCT07228403Short Bowel Syndrome (SBS)
DrugGlepaglutide
Zealand Pharma
Phase 3
28
Minnesota, Nebraska, Ohio, Tennessee
2025-12-11
Recruiting
Ultrasonic Neuromodulation of Cingulate Cortex for Fibromyalgia
NCT07226648Fibromyalgia
SPIRE Therapeutics Inc.
Not applicable
180
Michigan, Minnesota, Missouri, New York, Pennsylvania, Utah, West Virginia
2025-12-11
Recruiting
A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia
NCT07144163Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
DrugAtumelnant
Crinetics Pharmaceuticals Inc.
Phase 3
150
California, Colorado, Florida, Georgia, Illinois, Maryland, Michigan, Minnesota
2025-12-11
Recruiting
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC)
NCT07217717Pancreatic Ductal Adenocarcinoma (PDAC)
Drug[18F]FAPI-74 PET/CT
SOFIE
Phase 3
200
California, Florida, Indiana, Massachusetts, Minnesota, New York, Ohio, Pennsylvania
2025-12-11
Recruiting
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
NCT07007559Breast Cancer, Metastatic
DrugsEvorpacept·Eribulin·Herceptin·Vinorelbine
ALX Oncology Inc.
Phase 2
120
Arizona, California, Colorado, District of Columbia, Florida, Illinois, Michigan, Minnesota
2025-12-10
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
NCT07155187Non-Small Cell Lung Cancer, c-MET
DrugsTelisotuzumab Adizutecan·Osimertinib
AbbVie
Phase 2/3
490
Arkansas, California, Florida, Indiana, Minnesota, Nebraska, New Hampshire, New Jersey
2025-12-10
Recruiting
CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer
NCT07322094FIGO Stage III and IV Ovarian Cancer, Fallopian Tube Cancers, Primary Peritoneal Cancer
TORL Biotherapeutics, LLC
Phase 1/2
60
California, Minnesota, New York, North Carolina
2025-12-10
Recruiting
Phase 1 Study of CLR 125 in Triple Negative Breast Cancer
NCT07311993Breast Cancer
DrugCLR 131
Cellectar Biosciences, Inc.
Phase 1
60
Florida, Maryland, Minnesota, New Jersey
2025-12-05
Recruiting
Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
NCT07165132GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors
RayzeBio, Inc.
Phase 1
104
Arizona, Florida, Iowa, Kentucky, Minnesota, Missouri, Ohio, Oregon
2025-12-03
Recruiting
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
NCT06937229Alzheimer Disease, Agitation
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
650
Arizona, California, Florida, Georgia, Maryland, Massachusetts, Michigan, Minnesota
2025-12-02
Recruiting
Evaluation of the Q-Pad hrHPV Test System for Identifying Precancer
NCT07281599HPV Infection, HPV 16 Infection, High Risk HPV, Cervical Cancer Screening
Qurasense
Not applicable
450
Connecticut, Minnesota, Ohio
2025-12-01
Recruiting
Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
NCT07227012Carcinoma, Hepatocellular, Hepatocellular Cancer, Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma
DrugsPF-08634404·Yervoy·Ipilimumab
Pfizer
Phase 1/2
138
California, Florida, Illinois, Minnesota, Missouri, Nevada, North Carolina, Ohio
2025-12-01
Recruiting
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities
NCT07144852Actinic Keratosis
Sun Pharmaceutical Industries, Inc.
Phase 3
260
Arizona, California, Colorado, Florida, Idaho, Illinois, Indiana, Minnesota
2025-11-29
Recruiting
Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis
NCT07236099Prurigo Nodularis (PN)
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2
135
Alabama, Arizona, California, Florida, Indiana, Michigan, Minnesota, Nebraska
2025-11-27
Recruiting
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
NCT07227402Renal Cell Carcinoma
DrugsZanzalintinib·Belzutifan·Cabozantinib
Merck Sharp & Dohme LLC
Phase 3
904
Alaska, California, Maine, Maryland, Minnesota, Nebraska, North Carolina, Tennessee
2025-11-26
Recruiting
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
NCT06996782Advanced or Metastatic Non-small Cell Lung Cancer
DrugsRamucirumab·Rilvegostomig·Nab-paclitaxel·Pemetrexed
AstraZeneca
Phase 1/2
152
Arizona, California, Florida, Maryland, Michigan, Minnesota, Ohio, Rhode Island
2025-11-24
Active, closed
A Study to Evaluate How the Study Drug Moves Through the Body, Adverse Events, and How the Body Tolerates ABBV-547 Injections
NCT07232004Healthy Volunteer
AbbVie
Phase 1
121
Alabama, Arkansas, California, Florida, Illinois, Massachusetts, Minnesota, Missouri
2025-11-24
Active, closed
Safety and Efficacy of 2910 nm Fiber Laser Resurfacing and Laser-Coring
NCT07254884Rhytids, Skin Laxity
FA Corporation
Not applicable
40
Minnesota
2025-11-24
Recruiting
A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)
NCT07103018Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer Patients, Metastatic Castration-resistant Prostate Cancer, mCRPC, mCRPC
DrugDarolutamide
K36 Therapeutics, Inc.
Phase 1
144
California, Florida, Minnesota, New York, North Carolina, Ohio, South Carolina, Texas
2025-11-21
Recruiting
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp
NCT07144345Actinic Keratosis
Sun Pharmaceutical Industries, Inc.
Phase 3
160
California, Florida, Illinois, Indiana, Minnesota, Missouri, Oregon, South Carolina
2025-11-19
Recruiting
A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer
NCT06948448Colorectal Cancer
DrugsONO-4578·Leucovorin·Opdivo·Adrucil
Ono Pharmaceutical Co., Ltd.
Phase 2
144
Arizona, California, Colorado, Florida, Minnesota, Ohio, Pennsylvania, Texas
2025-11-18
Recruiting
Gene Therapy for HER-Positive Cancer (SENTRY-HER2)
NCT07192432HER2 Expressing Solid Tumors
Vironexis Biotherapeutics Inc.
Phase 1/2
27
California, Colorado, Florida, Minnesota, New Jersey, New York, Ohio, Pennsylvania
2025-11-18
Recruiting
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
NCT07217704Esophageal Cancer, Gastric Cancer (GC), Gastroesophageal Junction
Drug[18F]FAPI-74 PET/CT
SOFIE
Phase 3
200
California, Florida, Indiana, Massachusetts, Minnesota, New York, Ohio, Pennsylvania
2025-11-14
Active, closed
A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment
NCT07036523Idiopathic Pulmonary Fibrosis
Boehringer Ingelheim
Phase 2
81
Alabama, Florida, Iowa, Kansas, Minnesota, Missouri, New York, North Carolina
2025-11-13
Recruiting
Actinium Therapy for Late-stage Aggressive Sarcomas
NCT07156565Advanced Soft Tissue Sarcoma
Ratio Therapeutics, Inc.
Phase 1
48
California, Minnesota, New York, Ohio, Texas
2025-11-12
Recruiting
Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease
NCT07228364Autosomal Dominant Polycystic Kidney Disease
DrugAZD1613
AstraZeneca
Phase 1
40
Alabama, California, Florida, Kansas, Maryland, Minnesota, Texas
2025-11-10
Recruiting
Phase III Study to Assess the Safety and Efficacy of SL1002 for Osteoarthritis Knee Pain
NCT07226258Osteoarthritis Knee Pain
Saol Therapeutics Inc
Phase 3
150
California, Colorado, District of Columbia, Florida, Minnesota, North Carolina, Oklahoma, Oregon
2025-11-07
Recruiting
A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization
NCT07088926Bronchiectasis With Pseudomonas Aeruginosa Colonization
DrugAZD0292
AstraZeneca
Phase 2
435
California, Colorado, District of Columbia, Florida, Georgia, Kansas, Michigan, Minnesota
2025-11-06
Recruiting
Comparing the Safety and Efficacy of ASI-02 to Agitated Saline for Suspected Right-to-left Shunt
NCT06938347Right-To-Left Shunt
Agitated Solutions, Inc.
Phase 3
300
Illinois, Minnesota, Mississippi, New York, Wisconsin
2025-11-05
Recruiting
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
NCT07216105Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer
DrugsTrastuzumab·Cetuximab
Fate Therapeutics
Phase 1
119
California, Minnesota, Pennsylvania, Texas
2025-11-04
Active, closed
At-home Ultrasound Localized Therapy for Rheumatoid Arthritis Study [At-home ULTRA Study]
NCT07163221Rheumatoid Arthritis (RA)
DrugConventional Synthetic DMARD
SecondWave Systems Inc.
Not applicable
60
Arizona, California, Colorado, Minnesota
2025-11-03
Recruiting
CCM OPEN HF Registry
NCT07112924Heart Failure
Impulse Dynamics
Observational
5,500
Arizona, Florida, Kansas, Massachusetts, Michigan, Minnesota, Missouri, New Hampshire
2025-11-01
Recruiting
A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC
NCT06699121Primary Sclerosing Cholangitis (PSC)
LISCure Biosciences
Phase 2
87
California, Colorado, Iowa, Maryland, Minnesota, Tennessee, Washington
2025-11
Recruiting
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
NCT07182149HNSCC, ESCC, Esophageal Adenocarcinoma, Gastric Adenocarcinoma
Normunity AccelCo, Inc.
Phase 1
150
Colorado, Connecticut, District of Columbia, Massachusetts, Minnesota, Missouri, New Jersey, Ohio
2025-10-30
Active, closed
Early Feasibility Study (EFS) of Abbott's Balloon-expandable (BE) TAVI System for the Treatment of Severe, Symptomatic Aortic Stenosis
NCT07116551Symptomatic Severe Aortic Stenosis
Abbott Medical Devices
Not applicable
11
Kansas, Minnesota, New York
2025-10-30
Recruiting
Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment
NCT07007962Immune Thrombocytopenia
DrugRilzabrutinib
Sanofi
Phase 3
60
California, Louisiana, Massachusetts, Michigan, Minnesota, New York, Oregon, Utah
2025-10-24
Recruiting
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
NCT06899126Non-small Cell Lung Cancer
DrugsTrastuzumab deruxtecan·Pemetrexed·Keytruda·Pembrolizumab
Daiichi Sankyo
Phase 3
686
Alaska, California, Florida, Georgia, Hawaii, Illinois, Massachusetts, Minnesota
2025-10-24
Recruiting
A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer
NCT07027514Non Small Cell Lung Cancer
DrugsTolododekin alfa·Cetrelimab
Ankyra Therapeutics, Inc
Phase 1
60
Florida, Illinois, Indiana, Michigan, Minnesota, New York, North Carolina, Pennsylvania
2025-10-22
Recruiting
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
NCT07213791Ovarian Neoplasms, Breast Neoplasms, Pancreatic Intraductal Neoplasms, Colorectal Neoplasms
Eli Lilly and Company
Phase 1
241
California, Florida, Indiana, Maryland, Massachusetts, Michigan, Minnesota, Missouri
2025-10-22
Recruiting
ARC-IM System to Manage Symptomatic Blood Pressure Instability Secondary to Chronic Spinal Cord Injury
NCT07147296Spinal Cord Injuries, Blood Pressure Disorders
ONWARD Medical, Inc.
Not applicable
60
Arkansas, Colorado, Florida, Georgia, Kentucky, Maryland, Massachusetts, Minnesota
2025-10-17
Recruiting
Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)
NCT07115004Von Willebrand Disease (VWD)
DrugVGA039
Vega Therapeutics, Inc
Phase 3
60
Arkansas, California, Connecticut, Georgia, Michigan, Minnesota, North Carolina, Pennsylvania
2025-10-15
Recruiting
A Study of CTD402 in T-ALL/LBL Patients
NCT07070219Acute Lymphocytic Leukemia Refractory, Lymphoma, Lymphoblastic
Imviva Bio
Phase 1/2
118
California, Colorado, Illinois, Minnesota, New York, Tennessee, Texas
2025-10-07
Recruiting
Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
NCT07140900Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
DrugsXaluritamig·Abiraterone·Darolutamide
Amgen
Phase 1
60
California, Massachusetts, Minnesota, Ohio, Pennsylvania, South Carolina, Tennessee
2025-10-07
Recruiting
A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
NCT07023614Non-obstructive Hypertrophic Cardiomyopathy
Imbria Pharmaceuticals, Inc.
Phase 2
165
California, District of Columbia, Florida, Illinois, Maryland, Massachusetts, Michigan, Minnesota
2025-10-06
Recruiting
The Lilac Device Trial - IMPACT: A Clinical Investigation on IMproving Peripheral Neuropathy Induced by Chemotherapy With Advanced Compression Technology - A Safety and Efficacy Study
NCT07142304Chemotherapy Induced Peripheral Neuropathy (CIPN)
Luminate Medical, Inc.
Not applicable
142
California, Connecticut, Florida, Hawaii, Illinois, Indiana, Minnesota, New Jersey
2025-10-03
Active, closed
Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia
NCT07033481Nonfluent Variant Primary Progressive Aphasia (nfvPPA)
DrugNeflamapimod
EIP Pharma Inc
Phase 2
20
Illinois, Minnesota, New York, Ohio, Pennsylvania
2025-10-02
Recruiting
IVUS CHIP UPP Registry
NCT06625801Coronary Artery Disease, Coronary Artery Disease Risk High, Complex Coronary Artery Disease
ECRI bv
Observational
1,010
Arizona, California, Florida, Georgia, Illinois, Kentucky, Michigan, Minnesota
2025-09-30
Recruiting
Evaluation of a Non-Implanted Electrical Stimulation Device for Overactive Bladder (OAB)
NCT07195656Overactive Bladder (OAB)
FemPulse Corporation
Not applicable
151
California, Florida, Illinois, Kentucky, Maryland, Minnesota, Nebraska, North Carolina
2025-09-30
Recruiting
Clinical Course Of Disease In Participants With FA-CM
NCT06865482Friedreich Ataxia, Cardiomyopathy
Lexeo Therapeutics
Observational
65
California, Florida, Indiana, Massachusetts, Minnesota, Missouri, Ohio, Oregon
2025-09-30
Recruiting
A Study of AAVB-039 in Participants With Stargardt Disease (STGD1)
NCT07161544Stargardt Disease
AAVantgarde Bio Srl
Phase 1/2
75
Arizona, California, Florida, Minnesota, Texas, Utah
2025-09-29
Recruiting
A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease
NCT07190196Immunoglobulin G4 Related Disease
DrugRilzabrutinib
Sanofi
Phase 3
124
California, Florida, Georgia, Massachusetts, Michigan, Minnesota, New York, Ohio
2025-09-26
Active, closed
SPHERE Per-AF Post-Approval Study
NCT06858306Persistent Atrial Fibrillation
Medtronic Cardiac Ablation Solutions
Observational
200
Alabama, Florida, Georgia, Minnesota, New York, North Carolina, Ohio, Pennsylvania
2025-09-25
Recruiting
A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
NCT07123454B-cell Non-Hodgkin Lymphoma
AstraZeneca
Phase 1/2
91
California, Florida, Minnesota, New York, Ohio, South Carolina, Tennessee
2025-09-24
Recruiting
A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)
NCT06760546Hypothalamic Obesity, Multiple Pituitary Hormone Deficiency Genetic Form, Septo-Optic Dysplasia, Optic Nerve Hypoplasia
DrugSetmelanotide
Rhythm Pharmaceuticals, Inc.
Phase 3
39
Alabama, Colorado, Illinois, Massachusetts, Minnesota, New York, Pennsylvania, Washington
2025-09-23
Recruiting
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
NCT07109726Breast Cancer, Endometrial Cancer, Ovarian Cancer, Lung Squamous Cell Carcinoma
DrugFulvestrant
Terremoto Biosciences Inc.
Phase 1/2
205
California, Florida, Illinois, Massachusetts, Minnesota, Missouri, Nebraska, North Carolina
2025-09-23
Recruiting
Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)
NCT07157787Primary Membranous Nephropathy
Alexion Pharmaceuticals, Inc.
Phase 2
30
California, Minnesota, Texas
2025-09-19
Not yet open
LTFU for All Cell and Gene Therapy Studies
NCT06194461Hepatocellular Carcinoma, Prostate Cancer
DrugsAZD0754·AZD5851
AstraZeneca
Observational
64
Arizona, California, District of Columbia, Florida, Georgia, Kansas, Minnesota, Missouri
2025-09-17
Recruiting
Lumbar & Sacroiliac Fusion Study Involving Previously Implanted Devices
NCT07204288Fusion of Spine, Sacroiliac; Fusion
Spinal Simplicity LLC
Not applicable
500
Kansas, Minnesota
2025-09-11
Recruiting
Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC
NCT06726161Hepatocellular Carcinoma (HCC)
RayzeBio, Inc.
Phase 1/2
590
Alabama, Arizona, California, Florida, Kentucky, Maryland, Minnesota, Missouri
2025-09-05
Recruiting
Post-Approval Study of the Neuspera Sacral Neuromodulation System
NCT07144813Urinary Urgency Incontinence
Neuspera Medical, Inc.
Not applicable
116
California, Florida, Indiana, Kansas, Kentucky, Louisiana, Michigan, Minnesota
2025-09-03
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
NCT07023289Colorectal Cancer
DrugTelisotuzumab Adizutecan
AbbVie
Phase 2
140
Alabama, California, Florida, Illinois, Maryland, Massachusetts, Michigan, Minnesota
2025-09-02
Recruiting
A Study to Assess How Effective and Safe NVD003 is for Treating Patients With Congenital Pseudarthrosis of the Tibia.
NCT07112443Congenital Pseudarthrosis of Tibia
Novadip Biosciences
Phase 3
12
Arizona, California, Maryland, Minnesota
2025-09-02
Recruiting
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.
NCT06925321Invasive Mold Infections
DrugFosmanogepix
Basilea Pharmaceutica
Phase 3
234
Alabama, California, Florida, Illinois, Kentucky, Maryland, Michigan, Minnesota
2025-08-26
Recruiting
How's Your Balance?
NCT07412145Balance Assessment, Falls, Plantar Sensation
RxFunction Inc.
Observational
1,000
Minnesota
2025-08-23
Recruiting
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
NCT07154706Non-small Cell Lung Cancer (NSCLC)
DrugTaletrectinib
Nuvation Bio Inc.
Phase 3
180
California, District of Columbia, Florida, Idaho, Louisiana, Massachusetts, Minnesota, New York
2025-08-21
Recruiting
A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
NCT07081646Relapsed AL Amyloidosis, Refractory AL Amyloidosis, Light Chain Amyloidosis, Amyloidosis
DrugAZD0120
Alexion Pharmaceuticals, Inc.
Phase 1/2
91
Arizona, California, Florida, Massachusetts, Michigan, Minnesota, Missouri, New York
2025-08-18
Recruiting
A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia
NCT07086976Autoimmune Haemolytic Anaemia
DrugRilzabrutinib
Sanofi
Phase 3
90
Arizona, California, Connecticut, District of Columbia, Florida, Massachusetts, Michigan, Minnesota
2025-08-18
Active, closed
Aleniglipron Phase 2 Body Composition Study
NCT07169942Obesity, Overweight, or Chronic Weight Management
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Phase 2
71
Arizona, Illinois, Minnesota, Missouri, New York, North Carolina, Oklahoma, South Carolina
2025-08-15
Recruiting
Abbott Cephea Mitral Valve Disease Registry
NCT07069673Mitral Regurgitation, Mitral Stenosis, Mitral Valve Disease, Mitral Valve (MV) Regurgitation
Abbott Medical Devices
Observational
1,000
Alabama, Arizona, California, Georgia, Illinois, Indiana, Kansas, Minnesota
2025-08-13
Active, closed
A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)
NCT06985147Polycythemia Vera (PV)
DrugDISC-3405
Disc Medicine, Inc
Phase 2
60
Arizona, California, Florida, Minnesota, Missouri, North Carolina, Ohio, Oregon
2025-08-12
Recruiting
A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism
NCT07007793Primary Hyperaldosteronism
DrugBaxdrostat
AstraZeneca
Phase 3
250
California, Connecticut, Illinois, Maryland, Massachusetts, Michigan, Minnesota, Mississippi
2025-08-07
By invitation
Acolyte CTO-PCI Study: Imaging and Catheter System to Treat Patients With Coronary Chronic Total Occlusion, Who Have Persistent Symptoms Following Medical Therapy and Are Undergoing Percutaneous Coronary Interventional Procedures
NCT06795763Coronary Chronic Total Occlusions, Ischemic Heart Disease, Ischemic Heart Disease (IHD), Ischemic Heart Disease Chronic
Elumn8 Medical
Not applicable
115
Georgia, Minnesota, New York, Texas
2025-08-06
Active, closed
Study of EN-374 Gene Therapy in Participants With X-Linked Chronic Granulomatous Disease
NCT06876363X-Linked Chronic Granulomatous Disease
Ensoma
Phase 1/2
15
California, Florida, Massachusetts, Minnesota, New York, North Carolina, Utah
2025-08-05
Recruiting
Study Evaluating the Efficacy and Safety of Artesunate
NCT06853184CMV Infection
DrugsGanciclovir·Artesunate
Amivas Inc.
Phase 2
90
Massachusetts, Minnesota
2025-08-01
Recruiting
Evaluation of Accuracy of the Owlet OSS 3.0 Sensor in the Neonatal Population
NCT06771206Pulse Oximeter Validation
Owlet Baby Care, Inc.
Not applicable
20
Alabama, Minnesota
2025-08-01
Recruiting
Evaluating Patient Reported Outcomes and Surgeon Satisfaction With Ziplyft™
NCT07144761Blepharoplasty
Osheru Inc.
Not applicable
200
Florida, Minnesota, Pennsylvania, South Dakota, Wisconsin
2025-08
Recruiting
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
NCT07073547Multiple Myeloma
DrugAZD0120
AstraZeneca
Phase 1
40
Arizona, California, Colorado, Florida, Georgia, Iowa, Minnesota, Missouri
2025-07-31
By invitation
A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products
NCT06885424Solid Tumor Cancer, Solid Tumor, Unspecified, Adult, Colorectal Carcinoma, Colorectal Carcinoma (CRC)
A2 Biotherapeutics Inc.
Observational
400
Arizona, Minnesota, New York
2025-07-31
Recruiting
A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months
NCT07126262Hypochondroplasia
DrugVosoritide
BioMarin Pharmaceutical
Phase 2
60
Arizona, California, District of Columbia, Illinois, Maryland, Minnesota, Missouri, Texas
2025-07-30
Recruiting
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
NCT07024784Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer (PSOC)
DrugsIMGN151·Olaparib·Bevacizumab·Carboplatin
AbbVie
Phase 2
377
California, Colorado, Minnesota, New Jersey, New York, Ohio, Oklahoma, Oregon
2025-07-30
Recruiting
A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
NCT06721013Immune Thrombocytopenia (ITP)
DrugPirtobrutinib
Eli Lilly and Company
Phase 1/2
68
California, District of Columbia, Florida, Illinois, Louisiana, Minnesota, Texas
2025-07-30
Active, closed
Study to Evaluate the Safety, Pharmacology and Efficacy of WIN378 in Adults With Moderate or Severe Asthma
NCT07120503Asthma (Diagnosis)
DrugWIN378
Windward Bio
Phase 2
136
California, Florida, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Nebraska
2025-07-24
Recruiting
A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic
NCT07123038Rheumatoid Arthritis (RA), Hidradenitis Suppurativa (HS)
Sonoma Biotherapeutics, Inc.
Observational
36
California, Colorado, Illinois, Massachusetts, Minnesota, North Carolina, Texas
2025-07-22
Recruiting
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
NCT06570798Systemic Lupus Erythematosus, Active Refractory Rheumatoid Arthritis
DrugsUplizna·Inebilizumab·Blinatumomab
Amgen
Phase 2
220
Arizona, Colorado, Florida, Louisiana, Massachusetts, Minnesota, New York, Ohio
2025-07-16
Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
NCT06976216Alzheimer's Disease
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
586
California, Colorado, District of Columbia, Florida, Georgia, Illinois, Massachusetts, Minnesota
2025-07-14
Recruiting
Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258)
NCT06898515Acute Decompensated Heart Failure
DrugFurosemide
Reprieve Cardiovascular, Inc
Phase 3
400
California, Florida, Georgia, Illinois, Kansas, Kentucky, Michigan, Minnesota
2025-07-14
Active, closed
A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDG
NCT06892288Phosphomannomutase 2 Deficiency, PMM2-CDG
Glycomine, Inc.
Phase 2/3
50
Minnesota, New York, Pennsylvania, Washington
2025-07-09
Recruiting
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
NCT06915025Epithelial Ovarian Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
DrugsIMNN-001·Niraparib·Olaparib·Paclitaxel
Imunon
Phase 3
500
Florida, Louisiana, Minnesota, Missouri, Oregon, South Dakota, Tennessee, Washington
2025-07-09
Active, closed
A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine
NCT07010471Developmental and Epileptic Encephalopathy 1
DrugRelutrigine
Praxis Precision Medicines
Phase 3
160
California, Florida, Maryland, Minnesota, New Jersey, Pennsylvania
2025-07-09
Recruiting
Investigational Trial to Evaluate XC001 Delivered Via an Cardiac Catheter in Subjects With Chronic Angina.
NCT07048808Refractory Angina, Coronary Artery Disease
XyloCor Therapeutics, Inc.
Phase 2
106
Alabama, Arizona, Georgia, Massachusetts, Michigan, Minnesota, New York, North Carolina
2025-07-08
Recruiting
A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitis
NCT06999733Neurotrophic Keratitis
Krystal Biotech, Inc.
Phase 1/2
60
California, Indiana, Minnesota, Missouri, New Jersey, North Dakota, Pennsylvania
2025-07-07
Active, closed
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
NCT06981078Chronic Obstructive Pulmonary Disease
DrugVerekitug
Upstream Bio Inc.
Phase 2
666
California, Florida, Georgia, Illinois, Maryland, Minnesota, North Carolina, South Carolina
2025-07-02
Recruiting
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC)
NCT07082725Niemann-Pick Type C Disease
DrugNizubaglustat
Azafaros B.V.
Phase 3
72
California, Minnesota, Texas, Virginia
2025-06-30
Active, closed
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of GM1 Gangliosidosis or GM2 Gangliosidosis
NCT07082543Gangliosidoses, GM2, Gangliosidosis, GM1
DrugNizubaglustat
Azafaros B.V.
Phase 3
75
California, Minnesota, Texas, Virginia
2025-06-30
Not yet open
Efficacy and Safety of MSC-NTF (NurOwn) in Participants With Early Symptomatic ALS and Moderate Disease Presentation in ALS (ENDURANCE STUDY)
NCT06973629Amyotrophic Lateral Sclerosis (ALS), Amyotrophic Lateral Sclerosis
Brainstorm-Cell Therapeutics
Phase 3
200
Arizona, California, Colorado, Florida, Illinois, Massachusetts, Minnesota, Oregon
2025-06-30
Recruiting
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis
NCT07054515Niemann-Pick Type C Disease, GM1 Gangliosidosis, GM2 Gangliosidosis
DrugNizubaglustat
Azafaros B.V.
Phase 3
147
California, Minnesota, Texas, Virginia
2025-06-30
Recruiting
A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease
NCT06998524Von Willebrand Disease, Type 3
DrugEmicizumab
Hoffmann-La Roche
Phase 3
75
California, Florida, Kentucky, Minnesota, Missouri, Virginia
2025-06-27
Recruiting
A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
NCT06979362Heart Failure
DrugCDR132L
Novo Nordisk A/S
Phase 2
200
Alabama, Arizona, California, Colorado, Florida, Kentucky, Michigan, Minnesota
2025-06-27
Recruiting
PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
NCT06665100Hematologic Malignancies, Hematopoietic Stem Cell Transplant (HSCT)
Pulmotect, Inc.
Phase 2
100
California, Georgia, Maryland, Massachusetts, Michigan, Minnesota, New Jersey, New York
2025-06-27
By invitation
Global Open-Label Extension Study of Del-desiran for the Treatment of DM1
NCT07008469Myotonic Dystrophy Type 1, DM1, Myotonic Dystrophy, Myotonia
Avidity Biosciences, Inc.
Phase 3
199
California, Colorado, Florida, Indiana, Kansas, Maryland, Massachusetts, Minnesota
2025-06-26
Recruiting
A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
NCT06994806Solid Tumor Malignancies
DrugPembrolizumab
Kumquat Biosciences Inc.
Phase 1
84
Arizona, California, Colorado, Connecticut, Florida, Iowa, Minnesota, Ohio
2025-06-24
By invitation
Long-Term Extension Study of Vosoritide to Treat Children With Hypochondroplasia
NCT07073014Hypochondroplasia
DrugVosoritide
BioMarin Pharmaceutical
Phase 3
140
Arizona, California, Delaware, District of Columbia, Illinois, Maryland, Minnesota, Missouri
2025-06-20
Recruiting
Balance4Mobility: Effects of Walkasins Use in Individuals With Peripheral Neuropathy and Balance Problems
NCT06959277Peripheral Neuropathies, Peripheral Neuropathy Due to Chemotherapy, Peripheral Neuropathy With Type 2 Diabetes, Balance Control in Elderly
RxFunction Inc.
Not applicable
200
Arizona, Massachusetts, Minnesota, New York, Pennsylvania, Texas
2025-06-17
Recruiting
AERA Pediatrics Registry
NCT07071298Dysfunction of Eustachian Tube
Integra LifeSciences Corporation
Observational
300
California, Massachusetts, Michigan, Minnesota, Ohio, Pennsylvania, Texas, Utah
2025-06-17
Recruiting
Phase 1/2 Study of ABO-101 in Primary Hyperoxaluria Type 1 (redePHine)
NCT06839235Primary Hyperoxaluria Type 1 (PH1)
Arbor Biotechnologies
Phase 1/2
23
Minnesota
2025-06-16
Recruiting
A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer
NCT07030907Ovarian Cancer Recurrent, Ovarian Cancer, Platinum Resistant Ovarian Cancer
Outpace Bio, Inc.
Phase 1
30
Michigan, Minnesota, New York, Texas
2025-06-16
Recruiting
REgulatory T Cell Therapy to Achieve Immunosuppression REduction
NCT06552169Kidney Transplantation
Singulera Therapeutics Inc.
Phase 2
34
Arizona, Illinois, Minnesota
2025-06-13
Recruiting
Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis
NCT06668493Low-grade Upper Tract Urothelial Carcinoma
DrugNadofaragene Firadenovec
Ferring Pharmaceuticals
Phase 1/2
20
Arizona, California, Florida, Minnesota, New York, Pennsylvania, Texas
2025-06-12
Recruiting
A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
NCT06990880Neoplasms, Prostate
GlaxoSmithKline
Phase 1/2
85
Arizona, Colorado, Connecticut, Minnesota, New Jersey, Tennessee
2025-06-12
Recruiting
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non Interventional Cohort
NCT07024823Chronic Kidney Disease
AstraZeneca
Phase 1
124
California, Illinois, Michigan, Minnesota, Texas
2025-06-09
Recruiting
Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)
NCT06891443Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis, Sensation Disorders
DrugSepofarsen
Laboratoires Thea
Phase 3
32
California, Florida, Iowa, Minnesota, Pennsylvania
2025-06-04
Active, closed
Evaluating Bladder CARE™, a New Non-Invasive Urine Test, for Bladder Cancer Detection in Inconclusive Cases
NCT06870253Bladder Cancer, Urothelial Carcinoma Bladder
Pangea Laboratory LLC
Observational
80
Minnesota
2025-06-03
Recruiting
Real-World Data Collection of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis When Used in Covered Endovascular Reconstruction of the Aortic Bifurcation (CERAB) to Treat Aortoiliac Occlusive Disease
NCT06872905Aortoiliac Occlusive Disease
W.L.Gore & Associates
Observational
158
California, Florida, Minnesota, New Jersey, New York, North Carolina, Ohio, Pennsylvania
2025-05-30
Recruiting
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
NCT06533579B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Vironexis Biotherapeutics Inc.
Phase 1/2
32
California, Colorado, Florida, Minnesota, New York, North Carolina, Ohio, Oregon
2025-05-30
Recruiting
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
NCT06973564Advanced Solid Tumors
DrugJAB-23E73
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2
294
Minnesota, Missouri, Ohio, Utah
2025-05-29
Active, closed
A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)
NCT06782373VEXAS, VEXAS Syndrome
DrugPacritinib
Swedish Orphan Biovitrum
Phase 2
156
Arizona, Massachusetts, Minnesota, New York, Ohio, Texas, Utah, Washington
2025-05-28
Recruiting
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
NCT06682793Solid Tumor, Adult, Colorectal Cancer, Non-Small Cell Lung, NSCLC (Non-small Cell Lung Cancer)
A2 Biotherapeutics Inc.
Phase 1/2
240
Arizona, California, Florida, Minnesota, Missouri, New York, Ohio, Washington
2025-05-22
Recruiting
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
NCT06876649Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
DrugPirtobrutinib
Eli Lilly and Company
Phase 4
787
Florida, Georgia, Illinois, Massachusetts, Minnesota, Nebraska, New York, North Carolina
2025-05-20
Recruiting
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
NCT06876662Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
DrugPirtobrutinib
Eli Lilly and Company
Phase 4
279
Florida, Georgia, Illinois, Massachusetts, Minnesota, Nebraska, New York, North Carolina
2025-05-20
Recruiting
A Study to Assess the Safety and Effectiveness of the UrOActive® Artificial Urinary sPHincter (AUS)
NCT06968741Stress Urinary Incontinence (SUI)
UroMems SAS
Not applicable
140
California, Minnesota, North Carolina, Ohio, Tennessee, Texas, Virginia
2025-05-19
Active, closed
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer
NCT06970847Prostate Cancer, Prostate Cancer Patients With Detectable PSA Following Prostatectomy, Prostate Cancer Recurrent, Prostate Cancer Patients Who Have Brachytherapy Seed Implant
Drug64Cu-SAR-bisPSMA
Clarity Pharmaceuticals Ltd
Phase 3
220
California, Florida, Illinois, Indiana, Louisiana, Minnesota, Missouri, Nebraska
2025-05-16
Recruiting
A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine
NCT06995729Acute Treatment of Migraine
Pfizer
Phase 1
16
District of Columbia, Georgia, Minnesota, Nebraska, New York, North Carolina, Ohio, Oklahoma
2025-05-16
Recruiting
A proof-of Concept Study to Assess Safety and Tolerability of HM15421/GC1134A in Patients With Fabry Disease
NCT06858397Fabry Disesase
GC Biopharma Corp
Phase 1/2
18
California, Kansas, Minnesota, Ohio, Pennsylvania, Virginia
2025-05-14
Active, closed
A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone
NCT06806852Head and Neck Squamous Cell Carcinoma
DrugsBI 770371·Cetuximab·Pembrolizumab
Boehringer Ingelheim
Phase 1
91
Kentucky, Minnesota, Ohio
2025-05-14
Recruiting
A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
NCT06798012Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Takeda
Phase 2
36
California, Florida, Georgia, Massachusetts, Minnesota, Missouri, Pennsylvania, Texas
2025-05-14
Recruiting
Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults And Adolescent Participants Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)
NCT06822426Central Line Associated Blood Stream Infections (CLABSI)
Drugs(taurolidine and heparin) catheter lock·Heparin
CorMedix Therapeutics
Phase 3
200
California, District of Columbia, Florida, Georgia, Illinois, Iowa, Maryland, Minnesota
2025-05-14
Recruiting
Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
NCT06801236Prostate Cancer (Adenocarcinoma), mCRPC (Metastatic Castration-resistant Prostate Cancer)
Acerand Therapeutics (Hong Kong) Limited
Phase 1
88
California, Florida, Maryland, Massachusetts, Minnesota, Nebraska, South Carolina, Washington
2025-05-12
Active, closed
A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight
NCT06962280Type 1 Diabetes, Obesity, Overweight
DrugTirzepatide
Eli Lilly and Company
Phase 3
465
California, Colorado, Florida, Iowa, Minnesota, Missouri, Nevada, North Carolina
2025-05-12
Active, closed
53-Week Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 With Mild to Severe Tibio-Femoral Osteoarthritis of the Knee
NCT06865079Osteoarthritis (OA) of the Knee
OrthoTrophix, Inc
Phase 2
270
Arizona, California, Florida, Georgia, Kansas, Kentucky, Louisiana, Minnesota
2025-05-09
By invitation
Specimen and Data Collection for a Novel Biomarker Combination for the Differential Diagnosis of Inflammatory Bowel Disease and Irritable Bowel Syndrome.
NCT07471490IBD (Inflammatory Bowel Disease), IBS (Irritable Bowel Syndrome), Gastrointestinal Symptoms
DiaSorin Inc.
Observational
300
Minnesota
2025-05-07
Recruiting
Safety of HRX215 in Patients After Minor and Major Liver Resection
NCT06638502Liver Resection, Colorectal Carcinoma Liver Metastases
HepaRegeniX GmbH
Phase 1/2
80
Maryland, Minnesota, North Carolina, Ohio
2025-05-06
Active, closed
Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe Onychomycosis
NCT07065773Onychomycosis of Toenail
DrugTrichostatin A
Vanda Pharmaceuticals
Phase 2
50
California, Colorado, Minnesota, Texas, Virginia
2025-05-05
Recruiting
Treatment of Moderate to Severe Refractory Crohn's Disease
NCT06721962Crohns Disease
DrugsTRX103·Cyclophosphamide
Tr1X, Inc.
Phase 1/2
39
Arizona, California, Florida, Illinois, Iowa, Kentucky, Michigan, Minnesota
2025-05-05
Recruiting
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
NCT06892548Advanced Lung Cancer
DrugsBNT324·Pumitamig
BioNTech SE
Phase 1/2
594
Arizona, California, Colorado, Florida, Iowa, Minnesota, New Jersey, New York
2025-05-02
Recruiting
Evaluation of Enhanced Lithotripsy System (ELS) in the Treatment of Urinary Stones, A Pivotal Trial
NCT06942949Kidney Calculi; Ureteral Calculi
Avvio Medical
Not applicable
101
Arizona, Arkansas, California, Florida, Georgia, Illinois, Kansas, Minnesota
2025-05-01
Recruiting
A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
NCT06626919Muscular Diseases, Neuromuscular Manifestations, Autoimmune, Autoimmune Diseases
DrugsAnitocabtagene Autoleucel·Fludarabine·Cyclophosphamide
Arcellx, Inc.
Phase 1
30
California, Florida, Michigan, Minnesota, New York, Ohio, Oregon, Pennsylvania
2025-04-30
Active, closed
An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment
NCT06883240Von Willebrand Disease, Type 3
DrugsActivated Prothrombin Complex·Recombinant Factor VIIa
Hoffmann-La Roche
Observational
44
California, Minnesota, Missouri
2025-04-29
Recruiting
Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors
NCT06963281Solid Tumors
Fortvita Biologics (USA)Inc.
Phase 1
285
Arizona, Florida, Minnesota, New York, Texas
2025-04-29
Recruiting
Lead-212 PSV359 Therapy for Patients With Solid Tumors
NCT06710756Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Esophageal Cancer, Colorectal Cancer
Perspective Therapeutics
Phase 1/2
112
Florida, Kansas, Kentucky, Minnesota, Missouri, Nebraska, Ohio, Pennsylvania
2025-04-28
Recruiting
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
NCT06906341Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms, Endometrial Cancer
DrugsNab-paclitaxel /m^2·Relacorilant·Bevacizumab
Corcept Therapeutics
Phase 2
270
Alabama, California, Florida, Minnesota, Missouri, New Mexico, Ohio, Oregon
2025-04-11
Recruiting
An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome
NCT05066217Lennox Gastaut Syndrome
DrugClemizole HCl
Epygenix
Phase 3
260
Arkansas, California, Florida, Illinois, Kentucky, Michigan, Minnesota, Nebraska
2025-04-09
Recruiting
CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)
NCT06708299Recurrent Pericarditis
Cardiol Therapeutics Inc.
Phase 3
110
Arizona, California, Florida, Illinois, Maryland, Massachusetts, Minnesota, New York
2025-04-07
Recruiting
AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis
NCT06665165ALS
Amylyx Pharmaceuticals Inc.
Phase 1
48
California, District of Columbia, Florida, Massachusetts, Minnesota, Pennsylvania, Tennessee, Texas
2025-04-07
Recruiting
FORWARD CAD IDE Study
NCT06662500Coronary Arterial Disease (CAD)
Shockwave Medical, Inc.
Not applicable
408
California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Massachusetts, Minnesota
2025-04-04
Active, closed
Safety and Efficacy Study of Sivopixant, Acetazolamide and SASS-001 in Sleep Apnea
NCT06776432Sleep Apnea
DrugAcetazolamide
Shionogi
Phase 2
60
California, Florida, Massachusetts, Michigan, Minnesota, Ohio, South Carolina, Texas
2025-04-02
Active, closed
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
NCT06863961Atopic Dermatitis
DrugAfimkibart
Hoffmann-La Roche
Phase 2
162
California, Florida, Georgia, Indiana, Michigan, Minnesota, New Jersey, New York
2025-04-01
Active, closed
A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease
NCT06807463Celiac Disease
DrugTEV-53408
Teva Branded Pharmaceutical Products R&D LLC
Phase 2
50
California, Colorado, Florida, Georgia, Louisiana, Michigan, Minnesota, New York
2025-03-31
Recruiting
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
NCT06644781Esophageal Squamous Cell Carcinoma
DrugsIfinatamab Deruxtecan·Irinotecan·Docetaxel·Paclitaxel
Daiichi Sankyo
Phase 3
510
Arizona, California, Michigan, Minnesota, Missouri, New Jersey, New York, Pennsylvania
2025-03-27
Active, closed
Siegel™ Transcatheter Aortic Valve Replacement System (TAVR) Early Feasibility Study
NCT06680427Aortic Stenosis Symptomatic
MiRus
Not applicable
30
California, Florida, Georgia, Minnesota, New Jersey, New York, Ohio
2025-03-26
Recruiting
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
NCT06810544Non Small Cell Lung Cancer, Glioma Glioblastoma Multiforme, Glioma, Malignant, Solid Tumor
DrugAbemaciclib
Tango Therapeutics, Inc.
Phase 1/2
191
Arizona, California, District of Columbia, Florida, Illinois, Massachusetts, Minnesota, New York
2025-03-24
Recruiting
Ultra-High Frequency - Electrocardiogram (UHF-ECG) for the Diagnosis of Ventricular Electrical Dyssynchrony (VED)
NCT06641362Bradycardia, Heart Failure, Ventricular Dysfunction
VDI Technologies
Observational
360
Arizona, Illinois, Minnesota, Ohio, Texas, Virginia
2025-03-18
Recruiting
BioPoly® Partial Resurfacing Knee Implant IDE
NCT06915363Knee Pain Chronic, Knee Osteoarthritis, Cartilage Damage, Cartilage Defects of the Knee
BioPoly LLC
Not applicable
152
Indiana, Minnesota, Missouri
2025-03-17
Recruiting
A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
NCT06950034Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2
Solu Therapeutics, Inc
Phase 1
105
California, Florida, Massachusetts, Minnesota, Oregon, Tennessee, Texas
2025-03-13
Active, closed
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA
NCT06868290ANCA Associated Vasculitis (AAV)
DrugRapcabtagene autoleucel
Novartis Pharmaceuticals
Phase 2
126
Colorado, Florida, Illinois, Massachusetts, Michigan, Minnesota, North Carolina, Oregon
2025-03-13
Recruiting
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
NCT06792695Metastatic Colorectal Cancer
DrugsFOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan)·Volrustomig·Bevacizumab
AstraZeneca
Phase 2
80
Arizona, California, District of Columbia, Illinois, Maryland, Massachusetts, Minnesota, New Jersey
2025-03-12
Recruiting
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
NCT06615479Relapsed or Refractory Multiple Myeloma (RRMM)
DrugsArlo-cel·Carfilzomib·Pomalidomide·Daratumumab
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3
440
Alabama, California, District of Columbia, Florida, Georgia, Louisiana, Massachusetts, Minnesota
2025-03-12
Recruiting
Parent-Child EF Intervention
NCT06924307Cognitive Intervention to Promote Healthy Development of Executive Function (EF) Skills in Young Children
Koronis Biomedical Technologies
Not applicable
140
Minnesota, New York
2025-03-10
Recruiting
A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT06879041Metastatic Castration-Resistant Prostate Cancer
DrugAZD2287
AstraZeneca
Phase 1
136
California, Florida, Illinois, Louisiana, Massachusetts, Minnesota, Nebraska, New York
2025-03-10
Active, closed
Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy
NCT06736418Small-Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Carcinoma of the Lung
Abdera Therapeutics Inc.
Phase 1
17
California, Florida, Maryland, Massachusetts, Minnesota, New York, Texas, Utah
2025-03-10
Recruiting
Alleviant ALLAY-HFrEF Study
NCT06812533Heart Failure
Alleviant Medical, Inc.
Not applicable
350
California, Florida, Georgia, Illinois, Louisiana, Massachusetts, Minnesota, Missouri
2025-03-10
Recruiting
52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism
NCT06689085Hypogonadism, Male
Halozyme Therapeutics
Phase 3
100
California, Colorado, Florida, Illinois, Massachusetts, Minnesota, Missouri, Nevada
2025-03-07
Active, closed
A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy
NCT06848231Multiple System Atrophy
Dasher Neuroscience Inc.
Phase 2
75
California, Massachusetts, Minnesota, New York, Tennessee, Texas
2025-03-03
Recruiting
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
NCT06731478Gastric Cancer, Gastroesophageal Junction Cancer
DrugsTrastuzumab deruxtecan·Trastuzumab·Keytruda·Pembrolizumab
Daiichi Sankyo
Phase 3
726
Connecticut, Illinois, Kansas, Maryland, Massachusetts, Michigan, Minnesota, New York
2025-02-27
Active, closed
A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC
NCT06745323Small Cell Lung Cancer (SCLC)
DrugTarlatamab
Amgen
Phase 2
252
California, Connecticut, Florida, Illinois, Minnesota, New York, North Carolina, Pennsylvania
2025-02-26
Recruiting
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
NCT06646276Extensive-Stage Small Cell Lung Cancer
DrugsEtoposide·Atezolizumab·Nivolumab·Carboplatin
Bristol-Myers Squibb
Phase 3
530
Alabama, Arkansas, Florida, Georgia, Illinois, Minnesota, New Mexico, North Carolina
2025-02-25
Recruiting
An Extension Study to Evaluate Safety and Efficacy of Atumelnant in Participants With Congenital Adrenal Hyperplasia
NCT06712823Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
DrugAtumelnant
Crinetics Pharmaceuticals Inc.
Phase 2
200
Minnesota, North Carolina, Pennsylvania
2025-02-25
Recruiting
Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant
NCT06938867E Coli Infections, Allogenic Transplant Patients
SNIPR Biome Aps.
Phase 1/2
24
California, Maryland, Minnesota, New York, Pennsylvania, Texas, Washington
2025-02-25
Recruiting
Sensing Physiological Symptoms of Opioid Withdrawal and Cravings in Patients With Opioid Use Disorder
NCT06487533Opioid Withdrawal, Opioid Use Disorder
Spark Biomedical, Inc.
Observational
20
Minnesota, Ohio
2025-02-19
Recruiting
The PeriCut Catheter System Early Feasibility Study (REIMAGINE-HFpEF)
NCT06702501Heart Failure With Preserved Ejection Fraction
Heart Failure Solutions, Inc.
Not applicable
10
Minnesota
2025-02-17
By invitation
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)
NCT06908226Developmental and Epileptic Encephalopathy
DrugBexicaserin
Longboard Pharmaceuticals
Phase 3
324
Arkansas, California, Colorado, Florida, Idaho, Maryland, Massachusetts, Minnesota
2025-02-12
Active, closed
Pivotal Clinical Trial Evaluating the Safety and Efficacy of the Fully Implanted Acclaim Cochlear Implant
NCT06699797Sensori-Neural Deafness, Sensorineural Hearing Loss, Sensorineural Hearing Loss (Disorder), Sensorineural Hearing Loss, Bilateral
Envoy Medical Corporation
Not applicable
56
Arizona, California, Florida, Minnesota, Ohio, Oklahoma, South Carolina
2025-02-06
Recruiting
A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
NCT06720987KRAS G12C Mutation, KRAS G12S Mutation, Solid Tumor Malignancies, CRC (Colorectal Cancer)
DrugsKQB198·Cetuximab
Kumquat Biosciences Inc.
Phase 1
140
Arizona, Colorado, Florida, Massachusetts, Michigan, Minnesota, Ohio, Oklahoma
2025-02-04
Active, closed
A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)
NCT06812325Thyroid Eye Disease (TED)
DrugVRDN-003
Viridian Therapeutics, Inc.
Phase 3
320
Arizona, California, Florida, Illinois, Massachusetts, Michigan, Minnesota, Missouri
2025-02-03
Recruiting
BOOM-IBD2 Pivotal Clinical Trial
NCT06571669Ulcerative Colitis, Inflammatory Bowel Diseases
Boomerang Medical
Not applicable
137
California, Kansas, Minnesota, Mississippi, Missouri, Nevada, New York, North Carolina
2025-01-31
Recruiting
An Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis
NCT06836232Recurrent Pericarditis
Zomagen Biosciences Ltd.
Phase 2
50
California, Florida, Illinois, Massachusetts, Minnesota, New York, Ohio, Texas
2025-01-28
Recruiting
US National TOP Registry
NCT06513091Lung Transplant
TransMedics
Observational
10,000
Arizona, California, Minnesota, North Carolina, Texas, Wisconsin
2025-01-23
Active, closed
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
NCT06777316Intrahepatic Cholangiocarcinoma (Icc), Cholangiocarcinoma, Other Solid Tumors, Adult, FGFR2 Gene Fusion/Rearrangement
Cogent Biosciences, Inc.
Phase 1/2
110
California, Florida, Illinois, Massachusetts, Minnesota, Ohio, Pennsylvania, Tennessee
2025-01-22
Recruiting
Brain Training for Substance Use Disorders
NCT06870110Opioid Use Disorder
Neurotype Inc.
Not applicable
40
Minnesota
2025-01-17
Recruiting
Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma
NCT06517888Vestibular Schwannoma
Akouos, Inc.
Phase 1/2
27
Maryland, Minnesota, Tennessee, Texas
2025-01-17
Recruiting
AAV Gene Therapy Clinical Study in Adult Classic PKU (PHEdom)
NCT06332807Phenylketonurias
NGGT INC.
Phase 1/2
12
California, Minnesota, New Jersey, Pennsylvania, Texas
2025-01-10
Recruiting
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis
NCT06807424Arthritis, Psoriatic
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 3
750
Arizona, Arkansas, Florida, Illinois, Maryland, Massachusetts, Minnesota, New Mexico
2025-01-09
By invitation
Utility and Effectiveness of Polygenic Risk Scoring (PRS) for Coronary Artery Disease (CAD)
NCT06542432Coronary Artery Disease, Polygenic Risk Score, Heart Diseases, Coronary Disease
MyOme
Not applicable
1,000
Minnesota, Pennsylvania
2025-01-01
Recruiting
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
NCT06600321Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
DrugsKeytruda·Pembrolizumab
Alnylam Pharmaceuticals
Phase 1
158
Arizona, California, Florida, Georgia, Illinois, Michigan, Minnesota, New York
2024-12-30
Recruiting
A Study of ADRX-0405 in Subjects With Select Advanced Solid Tumors
NCT06710379Solid Tumors
Adcentrx Therapeutics
Phase 1
68
California, Michigan, Minnesota, Texas, Utah, Virginia
2024-12-30
Active, closed
Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Therapy-resistant CVU (Phase III)
NCT06489028Venous Leg Ulcer
RHEACELL GmbH & Co. KG
Phase 3
250
Florida, Massachusetts, Minnesota
2024-12-26
Active, closed
A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations
NCT06653842Cutaneous Venous Malformations
DrugQTORIN rapamycin anhydrous
Palvella Therapeutics, Inc.
Phase 2
15
California, Colorado, Maryland, Minnesota, North Carolina, Ohio, Pennsylvania, Utah
2024-12-20
Not yet open
Clinical Data Collection for Obstetric Ultrasound Algorithms
NCT06742229Pregnancy
Caption Health, Inc.
Not applicable
700
Minnesota, Texas
2024-12-20
Recruiting
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
NCT06500702Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion
DrugsBrivekimig·Frexalimab·Rilzabrutinib
Sanofi
Phase 2
84
Alabama, California, Florida, Georgia, Illinois, Michigan, Minnesota, Nevada
2024-12-19
Recruiting
RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
NCT06359041Generalized Myasthenia Gravis (gMG)
DrugRese-cel
Cabaletta Bio
Phase 1/2
24
California, Colorado, Florida, Illinois, Kansas, Massachusetts, Minnesota, New York
2024-12-17
Recruiting
Suprachoroidal Administration in Subjects With Metastases to the Choroid
NCT06643884Eye Cancer, Primary Cancer
DrugBel-sar
Aura Biosciences
Phase 2
24
California, Florida, Massachusetts, Michigan, Minnesota, Ohio, Pennsylvania, Tennessee
2024-12-16
Recruiting
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
NCT06657222Advanced Solid Tumors, HNSCC, SCLC, NSCLC
Gilead Sciences
Phase 1/2
250
Connecticut, Florida, Massachusetts, Minnesota, Missouri, New York, Ohio, Texas
2024-12-13
Recruiting
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
NCT06463028Endometrial Cancer
DrugsSerabelisib·Sapanisertib·Paclitaxel
Faeth Therapeutics
Phase 2
40
California, Florida, Maryland, Minnesota, New York, Ohio, Oregon, Pennsylvania
2024-12-12
Active, closed
A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease
NCT06734234Kidney Disease
GlaxoSmithKline
Phase 1
86
Minnesota
2024-12-11
Recruiting
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.
NCT05421858Candidemia, Candidiasis, Invasive
DrugsCaspofungin·Fosmanogepix·Fluconazole
Basilea Pharmaceutica
Phase 3
450
Alabama, California, Georgia, Indiana, Kentucky, Maryland, Michigan, Minnesota
2024-12-11
Recruiting
A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)
NCT06630234Gastrointestinal Stromal Tumor (GIST)
Deciphera Pharmaceuticals, LLC
Phase 1/2
120
Arizona, California, Colorado, Florida, Massachusetts, Michigan, Minnesota, New York
2024-12-10
Recruiting
A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors
NCT06625593Advanced Solid Tumor
BeOne Medicines
Phase 1
168
California, Connecticut, Minnesota, Texas, Washington, Wisconsin
2024-12-09
Active, closed
The JenaValve ALIGN-AR LVAD Registry
NCT06594705Aortic Regurgitation, Aortic Valve Insufficiency, Aortic Insufficiency, Aortic Valve Disease
JenaValve Technology, Inc.
Not applicable
50
California, District of Columbia, Georgia, Illinois, Michigan, Minnesota, Missouri, New York
2024-12-09
Recruiting
First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.
NCT06603844Solid Tumor
Corbus Pharmaceuticals Inc.
Phase 1/2
156
Alabama, Arizona, California, Colorado, Florida, Illinois, Minnesota, Nebraska
2024-12-04
Active, closed
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)
NCT06685757Antibody-mediated Rejection
DrugFelzartamab
Biogen
Phase 3
132
California, Colorado, Illinois, Kansas, Louisiana, Minnesota, Missouri, Nebraska
2024-12-03
Recruiting
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
NCT06526793B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)
DrugSurovatamig
AstraZeneca
Phase 2
270
Arizona, California, Florida, Illinois, Iowa, Kansas, Minnesota, Missouri
2024-11-27
Recruiting
A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
NCT06634589B-cell Malignancy, Relapsed Cancer, Refractory Cancer, B-cell Lymphoma
DrugsTacabrutideg·Mosunetuzumab·Sonrotoclax·Glofitamab
BeOne Medicines
Phase 1/2
80
Arizona, California, Florida, Kansas, Minnesota, Missouri, New York, Pennsylvania
2024-11-27
Recruiting
A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age
NCT06693895Chickenpox
DrugsMarketed varicella vaccine·Hepatitis A vaccine·PCV (pneumococcal conjugate vaccine) 13·PCV 20
GlaxoSmithKline
Phase 3
750
Arizona, California, Florida, Illinois, Kansas, Louisiana, Minnesota, Nebraska
2024-11-26
Active, closed
Safety and Effectiveness of the Luna System in People With Type 1 Diabetes Mellitus
NCT06627517Type 1 Diabetes Mellitus, Sleep Quality
Luna Diabetes
Not applicable
120
California, Colorado, Minnesota
2024-11-22
Active, closed
Phase 1 Study of GC1130A in Patients With Sanfilippo Syndrome Type A (MPS IIIA)
NCT06567769Sanfilippo Syndrome Type A
GC Biopharma Corp
Phase 1
9
California, Minnesota
2024-11-21
Recruiting
Early Feasibility Study of "HyperQureTM RDN System", Laparoscopic Renal Denervation Therapy, in Patients With Resistant Hypertension
NCT06526858Resistant Hypertension
DeepQure Inc.
Not applicable
15
California, Florida, Georgia, Michigan, Minnesota
2024-11-21
Recruiting
A Single-arm, Pivotal Study to Evaluate Acute Device and Technical Success of the CGuard Prime Carotid Stent System When Used in Conjunction to the ENROUTE Transcarotid Neuroprotection System in Patients Undergoing Carotid Artery Stenting Via the Transcarotid Artery Revascularization Approach
NCT06653387Carotid Artery Diseases
InspireMD
Not applicable
50
California, Indiana, Minnesota, Missouri, Montana, New York, Ohio
2024-11-20
Active, closed
Avalus Ultra Post-Approval Study (PAS)
NCT06506903Aortic Valve Disease
Medtronic Cardiac Surgery
Not applicable
190
Connecticut, Florida, Georgia, Illinois, Michigan, Minnesota, New York, Ohio
2024-11-20
Active, closed
Evaluation of a Simple-Prep Controlled Embolic
NCT06453642Embolization, Vascular Tumor, Renal Angiomyolipoma, Renal Cell Carcinoma
Fluidx Medical Technology, Inc.
Not applicable
114
California, Colorado, Illinois, Indiana, Minnesota, Missouri, New York, North Carolina
2024-11-18
Recruiting
An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer
NCT06693336Carcinoma, Non-Small-Cell Lung Cancer (NSCLC)
DrugPaclitaxel
ToLymph Inc.
Phase 2
42
Minnesota
2024-11-18
Recruiting
Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer
NCT06228053Metastatic Castration-resistant Prostate Cancer
DrugsSX-682·Xtandi·Enzalutamide
Syntrix Biosystems, Inc.
Phase 2
53
California, Michigan, Minnesota, North Carolina, Wisconsin
2024-11-18
Active, closed
A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)
NCT06537414Chronic Hepatitis B Virus Infection, Hepatitis B
DrugBepirovirsen
GlaxoSmithKline
Phase 2
283
California, Minnesota, New York, Pennsylvania
2024-11-11
Recruiting
A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study
NCT06531499Metastatic Castration-Resistant Prostate Cancer
DrugLu-PSMA
Novartis Pharmaceuticals
Phase 1
106
California, Minnesota, Missouri, Nebraska
2024-11-11
Active, closed
Abbott Medical - VERITAS Study
NCT06707688Atrial Fibrillation (AF), Stoke
Abbott Medical Devices
Not applicable
458
Arizona, Arkansas, Florida, Georgia, Kansas, Michigan, Minnesota, Nebraska
2024-11-07
Active, closed
A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
NCT06659640Hereditary Hemorrhagic Telangiectasia
DrugALN-6400
Alnylam Pharmaceuticals
Phase 1/2
89
Alabama, California, Florida, Indiana, Massachusetts, Minnesota, Missouri, North Carolina
2024-11-07
Recruiting
A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)
NCT05582993Von Willebrand Disease (VWD)
DrugsAdvate·Vonicog Alfa
Takeda
Phase 3
24
Alabama, Florida, Illinois, Indiana, Iowa, Michigan, Minnesota, Nevada
2024-11-06
Recruiting
A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
NCT06733935Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Antineutrophil Cytoplasmic Antibody-Associated Vasculitis, Rheumatoid Arthritis
DrugsNKX019·Fludarabine·Cyclophosphamide
Nkarta, Inc.
Phase 1/2
240
California, Florida, Illinois, Kansas, Michigan, Minnesota, New Jersey, New York
2024-11-04
Active, closed
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
NCT06644768Non-small Cell Lung Cancer, Lung Cancer
DrugsValemetostat·Valemetostat Tosylate·Keytruda·Pembrolizumab
Daiichi Sankyo
Phase 1/2
137
California, Florida, Kentucky, Minnesota, New York, Pennsylvania, Virginia
2024-10-30
Recruiting
A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma
NCT06630806Plasma Cell Myeloma Refractory
Sanofi
Phase 1
87
Arizona, Florida, Minnesota, New Jersey, Pennsylvania
2024-10-30
Active, closed
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis
NCT06655896Scleroderma, Diffuse
DrugsRapcabtagene autoleucel·Rituximab
Novartis Pharmaceuticals
Phase 2
96
California, Florida, Illinois, Iowa, Massachusetts, Michigan, Minnesota, Ohio
2024-10-29
Active, closed
A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)
NCT06508021Fibrodysplasia Ossificans Progressiva
DrugAndecaliximab
Ashibio Inc
Phase 2/3
92
California, Minnesota, Pennsylvania
2024-10-25
Active, closed
A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy
NCT06413706Glioma
DrugsAbemaciclib·Temozolomide
Eli Lilly and Company
Phase 2
45
California, Indiana, Maryland, Michigan, Minnesota, Rhode Island, Texas
2024-10-25
Active, closed
Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV.
NCT06321601Vasculitis
DrugAvacopan
Amgen
Phase 3
19
Georgia, Indiana, Minnesota, New York, North Carolina, Ohio, Pennsylvania, Texas
2024-10-22
Recruiting
Sacral Neuromodulation for Male Overactive Bladder (MOAB)
NCT06511141Overactive Bladder, Urinary Urgency Incontinence, Benign Prostatic Hyperplasia, Prostate Cancer
Axonics, Inc.
Not applicable
150
Alabama, Arizona, California, Florida, Louisiana, Maryland, Michigan, Minnesota
2024-10-22
Recruiting
ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome (MDS)
NCT06430385Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome
Ionis Pharmaceuticals, Inc.
Phase 1/2
48
California, Colorado, Maryland, Massachusetts, Minnesota, Pennsylvania, Tennessee, Texas
2024-10-21
Recruiting
Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT06549790Relapsed/Refractory Acute Myeloid Leukemia
Nerviano Medical Sciences
Phase 1
124
California, Colorado, Delaware, Georgia, Minnesota, Ohio, Texas
2024-10-16
Active, closed
A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma
NCT06637371Asthma
DrugAMG 691
Amgen
Phase 1
21
California, Florida, Georgia, Maryland, Massachusetts, Minnesota, North Carolina, Oklahoma
2024-10-16
Recruiting
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
NCT06562192Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer
Novartis Pharmaceuticals
Phase 1
162
Alabama, California, Florida, Massachusetts, Michigan, Minnesota, Texas, Washington
2024-10-15
Recruiting
A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia
NCT06525636X-linked Hypophosphatemia
Kyowa Kirin Co., Ltd.
Phase 1/2
39
California, Connecticut, Indiana, Minnesota, Tennessee
2024-10-09
Active, closed
Study of Single Doses of SBT777101 in Subjects With Hidradenitis Suppurativa
NCT06361836Hidradenitis Suppurativa
DrugSBT777101
Sonoma Biotherapeutics, Inc.
Phase 1
24
Massachusetts, Minnesota, Missouri, New York, North Carolina, Texas
2024-10-09
Recruiting
Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)
NCT05947955Acute Respiratory Distress Syndrome, Infections
BioAegis Therapeutics Inc.
Phase 2
600
California, Georgia, Illinois, Kentucky, Minnesota, Missouri, Nebraska, New York
2024-10-03
Active, closed
Heidelberg Engineering ANTERION Software Comparison Study
NCT06657716Eyes With Normal Anterior Segment, Eyes With Abnormal Anterior Segment
Heidelberg Engineering GmbH
Observational
60
Minnesota
2024-10-02
Recruiting
A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy
NCT06568237Multiple System Atrophy
DrugEmrusolmin
Teva Branded Pharmaceutical Products R&D LLC
Phase 2
350
California, District of Columbia, Florida, Illinois, Kansas, Massachusetts, Michigan, Minnesota
2024-10-02
Not yet open
Fiber Product for Gas, Bloating, and Bowel Regularity
NCT06642766Bloating, Bowel Irregularities, Bowel Gas
Bell Cinical Service
Not applicable
100
Minnesota
2024-10
Active, closed
Study of RN0361in Adult Healthy Subjects and Adult Hypertriglyceridemic Subjects
NCT06471543Hypertriglyceridemia, Familial Chylomicronemia Syndrome
Ikaria Bioscience Pty Ltd
Phase 1/2
108
Florida, Kentucky, Minnesota, Texas, Utah
2024-09-30
By invitation
Open-Label Extension Study to Assess GLM101 in PMM2-CDG Patients
NCT06657859Pmm2-CDG, Phosphomannomutase 2 Deficiency
Glycomine, Inc.
Phase 2
90
Minnesota, New York, Pennsylvania, Washington
2024-09-30
Active, closed
Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer
NCT06555796Prostate Cancer, High-risk Biochemical Recurrence, High Risk Biochemical Recurrence of Non-metastatic Castration-sensitive Prostate Cancer, Non-metastatic Castration-sensitive Prostate Cancer
DrugXaluritamig
Amgen
Phase 1
50
Minnesota, New York, North Carolina, Oregon, Pennsylvania, Texas, Washington
2024-09-23
Recruiting
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
NCT06542250B-cell Malignancies
DrugAZD5492
AstraZeneca
Phase 1/2
174
California, Massachusetts, Minnesota, New Jersey, New York, North Carolina, Texas, Washington
2024-09-18
Active, closed
Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)
NCT06497504Hepatitis B
DrugBepirovirsen
GlaxoSmithKline
Phase 2
153
California, Florida, Maryland, Minnesota, New Jersey
2024-09-17
Active, closed
Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
NCT06333951Thoracic Tumors, Non-small Cell Lung Cancer
DrugsAnvumetostat·Sotorasib·Pemetrexed·Paclitaxel
Amgen
Phase 1
49
California, Colorado, Connecticut, Minnesota, Missouri, Nevada, New York, Oklahoma
2024-09-17
Recruiting
The TRICURE EFS Study
NCT06506942Tricuspid Valve Regurgitation, Heart Valve Diseases, Cardiovascular Diseases
TRiCares
Not applicable
15
Georgia, Illinois, Michigan, Minnesota, New York, Ohio, South Carolina
2024-09-11
Recruiting
Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
NCT06423430Treatment Resistant Depression
Abbott Medical Devices
Not applicable
100
Alabama, California, Florida, Georgia, Illinois, Indiana, Massachusetts, Minnesota
2024-09-11
Recruiting
Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.
NCT06482905High-grade Glioma, WHO Grade Ⅳ Glioma
Tcelltech Inc.
Phase 1
52
Arizona, Florida, Minnesota
2024-09-04
Active, closed
A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma
NCT06381141Multiple Myeloma
DrugCLN-619
Cullinan Therapeutics Inc.
Phase 1
30
Arizona, Florida, Minnesota, New York, North Carolina, Texas
2024-09-03
Active, closed
A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma
NCT06425302Lymphoma, Follicular
DrugsEndoxan·Golcadomide·Pegylated liposomal doxorubicin·Bendamustine
Celgene
Phase 2
95
Alabama, Alaska, Arizona, California, District of Columbia, Florida, Kansas, Minnesota
2024-08-30
Active, closed
A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer
NCT06331299Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
UroGen Pharma Ltd.
Phase 3
99
California, District of Columbia, Georgia, Indiana, Minnesota, New Jersey, New York, South Carolina
2024-08-29
Active, closed
LMN-201 for Prevention of C. Difficile Infection Recurrence
NCT05330182Clostridioides Difficile Infection
Lumen Bioscience, Inc.
Phase 2/3
375
California, Connecticut, Florida, Illinois, Kentucky, Michigan, Minnesota, New York
2024-08-29
Recruiting
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
NCT06452277Advanced Non-small Cell Lung Cancer, HER2 Mutation
DrugsSevabertinib·Pemetrexed·Cisplatin·Carboplatin
Bayer
Phase 3
555
California, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan, Minnesota
2024-08-28
Active, closed
A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Ulcerative Colitis and Their Infants
NCT06126835Ulcerative Colitis
DrugOzanimod
Bristol-Myers Squibb
Observational
2,828
Minnesota
2024-08-26
Active, closed
A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)
NCT06564311Relapsing Multiple Sclerosis
DrugObexelimab
Zenas BioPharma (USA), LLC
Phase 2
93
Alabama, Arizona, California, Florida, Massachusetts, Minnesota, Missouri, New Jersey
2024-08-26
Active, closed
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
NCT06449222Locally Advanced Breast Cancer, Triple Negative Breast Cancer, Metastatic Triple Negative Breast Cancers
DrugsEribulin·Pumitamig·Gemcitabine·Paclitaxel
BioNTech SE
Phase 2
83
California, Colorado, Connecticut, Illinois, Minnesota, New Jersey, New York, Tennessee
2024-08-26
Active, closed
CONtiNuous glucosE Monitoring (CGM) in People wiTh Type 2 Diabetes Not on Insulin
NCT06601166Type 2 Diabetes
DexCom, Inc.
Not applicable
283
Colorado, Florida, Georgia, Indiana, Minnesota, Missouri, New York, North Carolina
2024-08-15
Active, closed
A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.
NCT06247995Breast Cancer
DrugsGa-NeoB·Lu-NeoB·Capecitabine
Novartis Pharmaceuticals
Phase 1/2
20
California, Minnesota, Texas, Wisconsin
2024-08-14
Recruiting
EFS of the DUO System for Tricuspid Regurgitation
NCT05913908Tricuspid Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease, Heart Valve Diseases
CroiValve Limited
Not applicable
15
Arizona, California, Georgia, Illinois, Kansas, Maine, Massachusetts, Minnesota
2024-08-13
Recruiting
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
NCT06435429Metastatic HER2-positive Breast Cancer
DrugsZanidatamab·Eribulin·Vinorelbine·Trastuzumab
Jazz Pharmaceuticals
Phase 3
550
Arizona, California, Colorado, District of Columbia, Florida, Massachusetts, Minnesota, Missouri
2024-08-13
Recruiting
SuperSaturated Oxygen Comprehensive Observational Registry
NCT06438315STEMI - ST Elevation Myocardial Infarction, AMI
TherOx
Observational
1,000
California, Florida, Illinois, Kansas, Michigan, Minnesota, New Jersey, New York
2024-08-13
Recruiting
Reducing Fluid Overload in Heart Failure Patients Using a Non-invasive, Renal Independent System
NCT06360380Chronic Heart Failure, CKD Stage 3
AquaPass Medical Ltd.
Not applicable
40
California, Minnesota, New York, North Carolina, Texas
2024-08-12
Recruiting
Melodi Matrix™ in Breast Reconstruction
NCT06027996Breast Reconstruction
Melodi Health, Inc.
Not applicable
702
California, Michigan, Minnesota, New York, Ohio, Pennsylvania, South Carolina, South Dakota
2024-08-09
Recruiting
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
NCT06332534Crohn's Disease
DrugUpadacitinib
AbbVie
Phase 3
110
California, Colorado, Connecticut, Illinois, Indiana, Massachusetts, Minnesota, New York
2024-08-08
Active, closed
Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib
NCT06531109Alopecia Areata
DrugRitlecitinib
Pfizer
Observational
450
Alabama, California, Florida, Iowa, Maryland, Massachusetts, Michigan, Minnesota
2024-08-07
Active, closed
Iptacopan in Patients With ANCA Associated Vasculitis
NCT06388941Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis
DrugsIptacopan·Rituximab
Novartis Pharmaceuticals
Phase 2
84
Arizona, Minnesota
2024-08-05
Recruiting
Innoventric Trillium™ Stent Graft Early Feasibility Study (EFS)
NCT06212193Tricuspid Regurgitation, Tricuspid Regurgitation Functional
Innoventric LTD
Not applicable
15
California, Michigan, Minnesota, New York, Ohio, Pennsylvania, Tennessee, Washington
2024-08-05
Active, closed
Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy
NCT06449209Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer
DrugsPumitamig·Topotecan·Etoposide·Paclitaxel
BioNTech SE
Phase 2
110
Alaska, California, Florida, Illinois, Indiana, Kentucky, Minnesota, Missouri
2024-08-05
Active, closed
Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)
NCT06100276Amyotrophic Lateral Sclerosis
UniQure Biopharma B.V.
Phase 1/2
20
Arizona, California, Florida, Georgia, Illinois, Kansas, Massachusetts, Minnesota
2024-08-01
Recruiting
VTP-1000 in Adults With Celiac Disease
NCT06310291Celiac Disease
Barinthus Biotherapeutics
Phase EARLY_PHASE1
45
California, Colorado, Florida, Maryland, Michigan, Minnesota, New York, North Carolina
2024-08-01
Active, closed
A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease
NCT06388083STGD1, Stargardt Disease 1
DrugTinlarebant
Belite Bio, Inc
Phase 2/3
60
Arizona, California, Florida, Massachusetts, Minnesota, New York, North Carolina, Pennsylvania
2024-07-31
Active, closed
SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations
NCT06239480Microcystic Lymphatic Malformation
DrugQTORIN rapamycin anhydrous
Palvella Therapeutics, Inc.
Phase 3
51
California, Georgia, Minnesota, New York, North Carolina, Ohio, Pennsylvania, Tennessee
2024-07-31
Recruiting
Investigations of Reproductive Cancers in Women
NCT06527157Uterine Cancer
PinkDx, Inc.
Observational
4,500
Alabama, California, Florida, Illinois, Indiana, Minnesota, Missouri, New York
2024-07-30
Active, closed
TRIcvalve biCAVal Valve System for Severe Tricuspid Regurgitation (TRICAV-I)
NCT06137807Tricuspid Regurgitation, Tricuspid Valve Disease
P+F Products + Features USA Inc.
Not applicable
50
Arizona, California, Florida, Illinois, Indiana, Louisiana, Massachusetts, Minnesota
2024-07-23
Recruiting
A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
NCT06362252Extensive Stage-small Cell Lung Cancer
DrugsIfinatamab Deruxtecan·Atezolizumab·Carboplatin
Daiichi Sankyo
Phase 1/2
123
Alabama, Arizona, California, Florida, Illinois, Michigan, Minnesota, New Hampshire
2024-07-22
Active, closed
tRNS Treatment for ADHD Symptoms
NCT06189703ADHD
Innosphere
Not applicable
146
Massachusetts, Minnesota, Texas
2024-07-15
Recruiting
A Prospective Research Investigation of Ischemia Using MCG
NCT06481943Acute Coronary Syndrome
SB Technology, Inc.
Observational
335
Minnesota, New York
2024-07-11
Recruiting
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
NCT06100744Juvenile Psoriatic Arthritis
DrugsSkyrizi·Risankizumab·Adalimumab
AbbVie
Phase 3
40
Arkansas, District of Columbia, Florida, Indiana, Minnesota, New York, North Carolina, Ohio
2024-07-08
Recruiting
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer
NCT06515470Breast Cancer
DrugFulvestrant
Biotheryx, Inc.
Phase 1
82
Minnesota, Nebraska, Texas, Utah, Virginia
2024-07-03
Recruiting
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
NCT06328777Systemic Sclerosis, Scleroderma, Interstitial Lung Diseases
DrugRese-cel
Cabaletta Bio
Phase 2/3
37
Connecticut, Florida, Illinois, Kansas, Michigan, Minnesota, New York, North Carolina
2024-07-02
Recruiting
A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)
NCT06431594Solid Tumors, Neoplasms
DrugMocertatug rezetecan
GlaxoSmithKline
Phase 1
675
Alabama, California, Florida, Kansas, Massachusetts, Michigan, Minnesota, New York
2024-07-02
Recruiting
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
NCT06465810Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR
AstraZeneca
Observational
1,850
California, Connecticut, District of Columbia, Illinois, Indiana, Maryland, Massachusetts, Minnesota
2024-06-25
Active, closed
ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency
NCT06462547Gene Mutations, Pseudoxanthoma Elasticum, Arterial Calcification, Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency
DrugINZ-701
Inozyme Pharma
Phase 2
22
Minnesota, New Jersey
2024-06-19
By invitation
A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent β-Thalassemia Who Received EDIT-301
NCT06363760Sickle Cell Disease, Transfusion-dependent Beta-Thalassemia, Hemoglobinopathies
Editas Medicine, Inc.
Observational
54
California, Colorado, Connecticut, Florida, Georgia, Minnesota, New York, North Carolina
2024-06-17
Active, closed
Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT06223516Multiple Myeloma
DrugEtentamig
AbbVie
Phase 1
60
Arizona, Florida, Michigan, Minnesota, North Carolina, Wisconsin
2024-06-17
Active, closed
Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis
NCT06097832Light Chain (AL) Amyloidosis
Nexcella Inc.
Phase 1/2
45
California, Georgia, Kansas, Massachusetts, Michigan, Minnesota, Missouri, New York
2024-06-05
Recruiting
Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease
NCT06270316Fabry Disease
UniQure Biopharma B.V.
Phase 1/2
20
Alabama, California, Georgia, Illinois, Minnesota, New York, Ohio, Pennsylvania
2024-06-05
Recruiting
Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
NCT05804370Ovarian Cancer
DrugGleolan
NX Development Corp
Phase 3
170
Arizona, Florida, Maryland, Minnesota, New York, Ohio, Pennsylvania, Virginia
2024-05-30
Active, closed
A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia
NCT05963074Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Lymphoma
DrugsVenclyxto·Ibrutinib·Venclexta·Venetoclax
Janssen Research & Development, LLC
Phase 2
333
California, Colorado, Florida, Idaho, Illinois, Iowa, Minnesota, Missouri
2024-05-30
Recruiting
Post-Market Clinical Study of Functional Motion Outcomes in Subjects Treated With the Minuteman Device
NCT06355791Degenerative Conditions of the Lumbar Spine, Lumbar Spinal Stenosis, Spondylolisthesis
Spinal Simplicity LLC
Not applicable
150
Georgia, Indiana, Kansas, Minnesota, Oregon, West Virginia
2024-05-29
Recruiting
CraniSeal Post Approval Study
NCT06406790Leak, Cerebrospinal Fluid
Pramand LLC
Phase 4
224
California, Florida, Georgia, Massachusetts, Minnesota, New York, South Carolina
2024-05-29
Recruiting
A Study of Pitolisant in Patients With Prader-Willi Syndrome
NCT06366464Prader-Willi Syndrome
DrugPitolisant
Harmony Biosciences Management, Inc.
Phase 3
134
California, Colorado, Delaware, Georgia, Illinois, Indiana, Maryland, Minnesota
2024-05-28
Recruiting
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
NCT06375044Relapsed or Refractory Multiple Myeloma
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
130
Arizona, California, Florida, Massachusetts, Minnesota, New York, North Carolina, Tennessee
2024-05-24
Recruiting
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis
NCT06293053Prurigo Nodularis
DrugDupilumab
Sanofi
Phase 3
18
California, Florida, Minnesota, Missouri, North Dakota, Oklahoma, Texas
2024-05-15
Recruiting
Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Limbal Stem Cell Deficiency
NCT06452316Limbal Stem Cell Deficiency
DrugCSB-001 Ophthalmic
Claris Biotherapeutics, Inc.
Phase 1
75
California, Indiana, Minnesota, Oregon, Texas
2024-05-15
Recruiting
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
NCT05419492Dravet Syndrome
DrugETX101
Encoded Therapeutics
Phase 1/2
47
California, Colorado, Florida, Illinois, Massachusetts, Michigan, Minnesota, North Carolina
2024-05-14
Recruiting
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
NCT06395519Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer
858 Therapeutics, Inc.
Phase 1/2
120
Arizona, Connecticut, Florida, Illinois, Massachusetts, Minnesota, New York, Ohio
2024-05-13
Active, closed
Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care
NCT06422689Asthma
AstraZeneca
Phase 4
1,511
California, Kentucky, Massachusetts, Michigan, Minnesota, North Carolina, Pennsylvania, Texas
2024-05-10
Active, closed
A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
NCT05973487Head and Neck Cancer, Cervical Cancer, Non-small Cell Carcinoma, Melanoma
TScan Therapeutics, Inc.
Phase 1
840
Arizona, California, Connecticut, Florida, Illinois, Kentucky, Michigan, Minnesota
2024-05-06
Active, closed
Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes
NCT06267391Type 2 Diabetes Mellitus, Type2diabetes, Diabetes Mellitus, Type 2, Diabetes
Endogenex, Inc.
Not applicable
350
Alabama, California, Florida, Illinois, Iowa, Maryland, Minnesota, New Jersey
2024-05-01
Recruiting
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
NCT06234605Renal Cell Carcinoma
DrugBelzutifan
HiberCell, Inc.
Phase 1
80
Arizona, California, Colorado, Connecticut, Michigan, Minnesota, Missouri, New York
2024-04-29
Active, closed
A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)
NCT06339008Perennial Allergic Rhinitis (PAR)
DrugLebrikizumab
Eli Lilly and Company
Phase 3
450
California, Colorado, Florida, Illinois, Kentucky, Michigan, Minnesota, Missouri
2024-04-26
Active, closed
PK and Safety Evaluation Study of SAP-001 in Adult Subjects With Normal and Impaired Renal Function
NCT06729853Gout, Hyperuricemia
DrugColchicine
Shanton Pharma Pte. Ltd.
Phase 1/2
32
Florida, Minnesota
2024-04-24
Active, closed
Blood Purification for the Treatment of Pathogen Associated Shock
NCT05011656Septic Shock
ExThera Medical Corporation
Not applicable
15
District of Columbia, Georgia, Michigan, Minnesota, Oregon, Pennsylvania, Texas
2024-04-19
Recruiting
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
NCT05908331In-Stent Restenosis, Cardiovascular Diseases, Coronary Artery Disease
Concept Medical Inc.
Not applicable
492
Alabama, Arizona, California, Connecticut, Florida, Georgia, Massachusetts, Minnesota
2024-04-16
Recruiting
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
NCT06330064Recurrent or Metastatic Solid Tumors
DrugIfinatamab Deruxtecan
Daiichi Sankyo
Phase 1/2
680
California, Illinois, Minnesota, New York, Tennessee, Texas, Utah, Virginia
2024-04-10
Recruiting
REFLECT Scoliosis System Post Approval Study
NCT06298812Idiopathic Scoliosis
Globus Medical Inc
Not applicable
100
Minnesota, New York
2024-04-08
Recruiting
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
NCT06462365Hematologic Malignancy, GvHD, GVHD,Acute, GVHD, Chronic
DrugTRX103
Tr1X, Inc.
Phase 1
36
California, Massachusetts, Minnesota, New York, Washington
2024-04-08
Recruiting
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
NCT06276491Ovarian Cancer, Endometrial Cancer, Germ Cell Tumor, Testicular Germ Cell Tumor
DrugXmAb541
Xencor, Inc.
Phase 1
282
California, Florida, Georgia, Illinois, Indiana, Michigan, Minnesota, New Jersey
2024-04-04
Recruiting
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
NCT05932862Advanced Solid Tumor
DrugOlaparib
Exelixis
Phase 1
429
California, Florida, Minnesota, Missouri, New Jersey, New York, Ohio, Oklahoma
2024-04-03
Recruiting
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
NCT06051695Solid Tumor, Adult, Colorectal Cancer, NSCLC, Non Small Cell Lung Cancer
A2 Biotherapeutics Inc.
Phase 1/2
474
Arizona, California, Florida, Minnesota, Missouri, New York, Ohio, Tennessee
2024-04-03
Active, closed
Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa
NCT06079372Hypophosphatasia
DrugsAsfotase alfa·ALXN1850
Alexion Pharmaceuticals, Inc.
Phase 3
43
Connecticut, Maryland, Minnesota, Missouri, North Carolina, Tennessee
2024-04-02
Recruiting
Clinical Safety and Efficacy of the VDyne Transcatheter Tricuspid Valve Replacement System for the Treatment of Tricuspid Regurgitation ( VISTA-US)
NCT05848284Tricuspid Regurgitation, Tricuspid Valve Disease, Tricuspid Valvular Disorders
VDyne, Inc.
Not applicable
30
California, Michigan, Minnesota, New York, Ohio, Oregon, South Carolina, Tennessee
2024-04-01
Recruiting
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion
NCT06158854Immunoglobulin Light Chain (AL) Amyloidosis
DrugEtentamig
AbbVie
Phase 1/2
76
Florida, Massachusetts, Minnesota, New York, North Carolina, Oregon, Tennessee, Washington
2024-04-01
Active, closed
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
NCT06291376Immunoglobulin A Nephropathy, IgAN
DrugRavulizumab
Alexion Pharmaceuticals, Inc.
Phase 3
584
Alabama, Arizona, California, Florida, Georgia, Louisiana, Massachusetts, Minnesota
2024-03-29
Recruiting
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
NCT06308978Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE)
DrugsFT819·Fludara·Bendamustine·Cytoxan
Fate Therapeutics
Phase 1
244
California, Florida, Kentucky, Minnesota, Nebraska, New York, North Carolina, Ohio
2024-03-28
Recruiting
Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults With PKP2 Mutation-associated ARVC
NCT06228924Arrhythmogenic Right Ventricular Cardiomyopathy
Tenaya Therapeutics
Phase 1
15
California, Colorado, Maryland, Massachusetts, Minnesota, New York, Ohio
2024-03-26
Recruiting
Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis
NCT06205121Pulmonary Sarcoidosis
Molecure S.A.
Phase 2
96
Alabama, Kansas, Maryland, Minnesota, Ohio, Pennsylvania, South Carolina
2024-03-21
Active, closed
Microfragmented Adipose Tissue Compared to Saline Injection for the Treatment of Knee Osteoarthritis
NCT06121882Knee Osteoarthritis, Osteo Arthritis Knee
Lipogems International spa
Phase 3
173
Arizona, California, Florida, Georgia, Louisiana, Maryland, Minnesota, Oklahoma
2024-03-15
Recruiting
CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults
NCT06305910Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent High Grade Glioma
DrugImiquimod
OX2 Therapeutics
Phase 1
24
Minnesota
2024-03-15
Recruiting
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
NCT05835310Systemic Lupus Erythematosus
DrugAnifrolumab
AstraZeneca
Phase 3
100
Arizona, California, District of Columbia, Illinois, Louisiana, Maryland, Minnesota, New York
2024-03-14
Active, closed
A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP
NCT04850118X-Linked Retinitis Pigmentosa
DrugAGTC-501
Beacon Therapeutics
Phase 2/3
85
Arizona, California, Florida, Indiana, Maryland, Massachusetts, Minnesota, North Carolina
2024-03-14
Recruiting
Smartphone Twelve-Lead ECG Utility In ST-Elevation Myocardial Infarction II
NCT06271577Myocardial Infarction, Ischemia, Myocardial Ischemia, Heart Diseases
AliveCor
Not applicable
1,000
Minnesota, Utah
2024-03-12
Recruiting
First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT06217822Advanced Metastatic Castration-resistant Prostate Cancer, Prostate Specific Membrane Antigen (PSMA) Expression
Bayer
Phase 1
198
California, Minnesota, Nebraska, Texas
2024-03-07
Recruiting
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis
NCT05646381Aortic Stenosis
DrugPelacarsen
Novartis Pharmaceuticals
Phase 2
502
Alabama, California, Florida, Kansas, Massachusetts, Michigan, Minnesota, New Jersey
2024-03-07
Active, closed
CLIP-IT Post-Market Study
NCT06203054Left Atrial Appendage Exclusion
Medtronic Cardiac Surgery
Not applicable
198
Georgia, Illinois, Indiana, Michigan, Minnesota, Missouri, New York, Ohio
2024-02-26
Recruiting
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT06172478Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer
DrugPatritumab deruxtecan
Daiichi Sankyo
Phase 2
740
California, Connecticut, Florida, Illinois, Maryland, Minnesota, Missouri, New York
2024-02-26
Recruiting
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT06121843Multiple Myeloma
DrugsArlocabtagene Autoleucel·Arlo-cel·Mezigdomide·Iberdomide
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1
187
Alabama, Arizona, California, Florida, Georgia, Massachusetts, Minnesota, Nebraska
2024-02-22
Active, closed
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
NCT06012435Carcinoma, Non-Small-Cell Lung
DrugsSigvotatug vedotin·Docetaxel
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
762
Alaska, California, Colorado, Florida, Illinois, Maryland, Massachusetts, Minnesota
2024-02-21
Active, closed
A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis
NCT06260709Transthyretin Amyloid Cardiomyopathy (ATTR CM)
DrugNNC6019-0001
Novo Nordisk A/S
Phase 2
80
Arizona, California, Florida, Illinois, Maryland, Minnesota
2024-02-20
Recruiting
Early Feasibility Study (EFS) Laplace Transcatheter Tricuspid Valve Replacement (TTVR) System
NCT06183684Tricuspid Regurgitation
Laplace Interventional, Inc
Not applicable
65
Arizona, California, Georgia, Minnesota, New Hampshire, New York, Ohio, Oklahoma
2024-02-19
Recruiting
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
NCT06121297Systemic Lupus Erythematosus, Lupus Nephritis
DrugRese-cel
Cabaletta Bio
Phase 1/2
28
California, Connecticut, Florida, Georgia, Illinois, Kansas, Massachusetts, Minnesota
2024-02-16
Recruiting
A Natural History Study in Participants With Congenital Myasthenic Syndromes (CMS) Due to Mutations in DOK7, MUSK, AGRN, or LRP4
NCT06078553Congenital Myasthenic Syndrome
argenx
Observational
100
California, Illinois, Massachusetts, Minnesota, Ohio, Pennsylvania
2024-02-13
Recruiting
Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Corneal Scars
NCT06257355Corneal Scar
DrugCSB-001 Ophthalmic
Claris Biotherapeutics, Inc.
Phase 1
20
California, Indiana, Minnesota, Oregon, Texas, Virginia
2024-02-05
Active, closed
A Study About Antibody Levels and Biomarkers in the Blood in People With Late-onset Pompe Disease
NCT06150820Pompe Disease (Late-onset)
Astellas Gene Therapies
Not applicable
119
Georgia, Kansas, Michigan, Minnesota, New Jersey, Ohio, Pennsylvania, Utah
2024-02-01
Active, closed
Registry of the Patient Experience for Carpal Tunnel Release
NCT06071468Carpal Tunnel Syndrome, CTS
Sonex Health, Inc.
Observational
1,424
Alabama, Arizona, Connecticut, Florida, Indiana, Massachusetts, Michigan, Minnesota
2024-01-26
Rows per page Showing 1–500 of 924
1 2 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 6 October 2026. https://priyalifescience.com/clinical-trials-usa/state/minnesota

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,118 studies in total at the last sync on 06 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 924 of those studies with a site in Minnesota.

How many clinical trials are recruiting in Minnesota?

493 of the 924 studies on this page are recruiting new participants as of the 06 Oct 2026, 03:16 UTC sync. A further 21 have not yet opened recruitment, 383 are active but closed to new participants, and 27 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Minnesota), 924 studies
PhaseStudiesRecruitingShare
Phase 32119422.8%
Phase 21497816.1%
Phase 1/21418715.3%
Not applicable1397115%
Phase 11329014.3%
Observational1135012.2%
Phase 2/326142.8%
Phase 41181.2%
Phase EARLY_PHASE1210.2%

Most active sponsors

Lead sponsors with the most studies (Minnesota)
Lead sponsorStudiesRecruiting
AstraZeneca3618
Novartis Pharmaceuticals2310
AbbVie1911
Eli Lilly and Company189
Bristol-Myers Squibb168
GlaxoSmithKline115
Abbott Medical Devices104
Daiichi Sankyo106
Hoffmann-La Roche104
Janssen Research & Development, LLC103
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.